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Abstract
Urgency urinary incontinence is a common symptom of overactive bladder (OAB) and
urinary tract infection (UTI), which can be triggered by extracellular adenosine triphosphate
(eATP) through purinergic signaling. Current treatments for OAB and UTI fail to consider
the potential impact of eATP. It is hypothesizes that certain commensal Lactobacillus spp.
can modulate levels of eATP released by pathogenic bacteria. This project examined
bacterial modulation of eATP during growth, the impact of prebiotics on lactobacilli growth,
and studied its reduction in an in vitro bladder infection model. Release and uptake of ATP
by a range of commensal and pathogenic bacteria was observed. Lactobacillus crispatus
ATCC 33820 and Lactobacillus gasseri KC-1 able to reduce supplemented and E. coli IA2derived ATP, was enhanced in culture with select prebiotics. This research builds a greater
understanding of the handling of eATP by bacteria and suggests a prebiotic-probiotic
application that could potentially improve bladder health.

Keywords
Urinary tract infection (UTI), Lactobacillus crispatus ATCC 33820, Lactobacillus gasseri
KC-1, Escherichia coli IA2, urinary urgency incontinence (UUI), overactive bladder (OAB),
microbiota, prebiotic, extracellular adenosine triphosphate (eATP), purinergic signalling.

ii

Summary for Lay Audience
A urinary tract infection (UTI) can occur in any part of the urinary system (kidneys, ureter,
bladder, or urethra). Not all UTIs have symptoms, but common ones are frequent urination,
pain, or burning with urination. Uropathogenic Escherichia coli frequently cause this
condition. Overactive bladder (OAB) is a collection of symptoms where one feels a frequent
and urgent need to urinate regardless of bladder volume and consequently may experience
urinary incontinence. Urgency urinary incontinence is the sensation to urinate regardless of
bladder volume, a symptom of both conditions. It is now becoming apparent that UTI and
OAB are somewhat associated with disruption of the normal commensal bacteria, the
microbiota. Each individual has a diverse microbiota containing trillions of microbes that are
compositionally different based on their location. For example, a healthy urogenital system
(urinary tract and genital tract) has a microbiota dominated by Lactobacillus species.
Commensal and pathogenic bacteria release adenosine triphosphate (ATP) into the
environment while they grow. All living things utilize ATP, which is a universal energy
molecule and is used to power cellular functions. Studies have shown that it is an important
signaling molecule for cell and host nervous systems. The release of ATP during growth
allows a bacterium to communicate with the host, influence the environment, and be taken up
later as an additional nutrient source. Several urinary-associated microbes and pathogenic E.
coli can release relatively large amounts of ATP, which may trigger the host nervous system
and potentially contribute to the feeling of urgency associated with UTIs and OAB.
However, some commensal lactobacilli take up ATP during growth or produce substances
that could reduce the adverse effects of ATP on the bladder. These lactobacilli can
potentially be administered as probiotics (live microorganisms that, when administered in
adequate amounts, confer a health benefit on the host) to reduce urinary ATP. Probiotics can
be supported, or beneficial indigenous strains promoted, by prebiotics. Prebiotics are
substrates selectively utilized by microorganisms conferring a health benefit. The use of
lactobacilli and prebiotics to address abundant urinary ATP was a previously unexplored and
promising method for urgency symptom management.
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Chapter 1

1

General Introduction

1.1 Focus of this thesis
Overactive bladder (OAB) and urinary tract infection (UTI) are common conditions that
affect millions globally and have similar symptom presentations 1,2. While these diseases are
quite different, they may share a common link. Urgency urinary incontinence (UUI) is a
symptom of both, where the patient feels an urgent need to urinate regardless of bladder
fullness and is rarely associated with the presence of uropathogenic bacteria. Adenosine
triphosphate (ATP), which is a known biomarker for UTIs, plays a significant role in bladder
regulation3,4. Current treatments for UUI and UTI fail to reduce extracellular ATP (eATP)
impact on the host. Bladder-associated potentially pathogenic bacteria and the urothelium
release ATP, which affects the uroepithelium and may be responsible for several bladder
symptoms5. Even when an infection is not present, bacterial strains in the urinary microbiota
can release ATP and potentially contribute to UUI5.
The release of ATP during the growth and establishment of infection by uropathogenic
bacteria may act as a virulence factor, triggering Ca2+ influx and smooth muscle contraction
through purinergic signaling 5,6. Purinergic signaling by ATP can regulate and control
bladder contraction thus creating a favorable environment for the bacteria by disrupting host
shedding and clearance of infection. Additionally, ATP release can potentially cause a
reduction of antimicrobial and bacteriocin production by commensal organisms that inhibit
Escherichia coli and reduce infectivity7–11. In theory, decreased bacteriocin production could
limit environmental competition, further enabling the establishment of infection.
Lactobacillus crispatus ATCC 33820 and Lactobacillus gasseri KC-1, when co-cultured with
E. coli IA2, lower the level of eATP, suggesting that these strains can potentially consume
ATP from culture5. Addressing the higher levels of eATP in the bladder environment with
lactobacilli uptake could reduce UUI and UTI symptoms previously unaddressed.
The goal of this project was to build a greater understanding of the role that eATP plays in
urogenital infections and explore the potential of a microbial therapeutic approach via a
prebiotic-probiotic application to reduce the effects of that ATP on the host. This work builds
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upon our previous studies5 and continues to focusing on L. crispatus ATCC 33820 and L.
gasseri KC-1 to reduce the high levels of ATP released during uropathogenic bacterial
growth. It is hypothesized that a greater understanding of this unique interaction could lead to
better management of UUI and UTI related symptoms.

1.2 Microbial role in bladder health
1.2.1

Human microbiota

The human microbiota is the entire collection of microorganisms that have colonized the
human body12; microbiome describes abiotic and biotic factors, including environmental
factors and microorganism genomes13. The microbiota consists of commensal, opportunistic
pathogens and pathogenic microorganisms, which vary based depending on the body site.
The microbiota can influence susceptibility to infectious disease, and the host-microbiome
interaction can impact infection outcomes12. Commensal members of the microbiota aid in
host resistance against infectious microorganisms through pathogen inhibition and
exclusion14,15. The microbiota plays a crucial role in host-infection interaction and
therapeutic modulation of the microbiome with probiotics, and prebiotics can treat and
prevent infectious diseases.

1.2.2

Bladder microbiota and its protective role

The bladder and urinary tract above the distal urethra in females were considered sterile until
2011 when a microbiota was characterized16,17 but this microbiota has not been considered
when addressing urological conditions. Since then, studies have found that the urinary
microbiota differs substantially between healthy and diseased individuals 18. The urinary
microbiome differs between sexes, with females having greater abundance of Lactobacilus
and Prevotella and males having greater Streptococcus presence19. Studies of the bladder
microbiota are limited due to the differences in the bladder and urethra microbiota. The
standard sampling method of voided urine does not accurately capture the bladder
microbiota, and the ideal method of catheterized urine is more invasive and less
accessible19,20.
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Despite the anatomical isolation of the bladder and vagina, they share an interconnected
urogenital microbiota, distinct from the gastrointestinal microbiota 21,22. The bladder and
vagina have highly similar microbial compositions that include commensal and pathogenic
microorganisms22. A healthy urogenital tract has a unique microbiota that is dominated by
Lactobacillus spp.23–25. Lactobacilli dominance is essential to a healthy urogenital
microbiota; the most common species are Lactobacillus crispatus, Lactobacillus gasseri,
Lactobacillus iners, and Lactobacillus jensenii23,24,26. The urogenital microbiota composition
(type and abundance) is impacted by age, hormones 27, environmental, and external factors
(antibiotics, birth control, intercourse, etc.)28. During sexually contracted infections, there is a
depletion of Lactobacillus; specifically, L. crispatus29. Interconnectivity of the bladder and
vaginal microbiota could mean that similar Lactobacillus loss occurs during infection of the
bladder, leading to an imbalance and increasing infection susceptibility. Decreased diversity
of the microbiome and/or decrease of lactobacilli abundance in the urogenital tract results in
a higher risk for urogenital infections18.

1.2.3

Probiotics

Probiotics are defined as live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host30. Health Canada acknowledges several bacterial species
as being associated with probiotic properties: Bifidobacterium (adolescentis, animalis,
bifidum, breve and longum), Lactobacillus (acidophilus, gasseri, johnsonii, and salivarius)
and Lacticaseibacillus (casei, fermentum, paracasei, rhamnosus, and plantarum) 31.* All
these species have been relatively well studied and are generally thought to confer health
benefits30. However, this does not account for strain differences within the same species, and
strains should be designated when calling a product probiotic.
Probiotic strains can positively impact the host through enhancing the epithelial barrier,
temporarily adhering to the intestinal mucosa, inhibiting pathogen adhesion, competitively
excluding pathogens, modulating the host immune system and producing anti-microbial
substances, amongst other potential mechanisms 30,32,33. However, probiotic mechanisms of

*

The genus Lactobacillus was split into 25 genera including the embedded genus Lactobacillus in April 2020137
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action are generally assessed at the strain level, and while many share certain positive
attributes, no single strain has every known probiotic feature.
Strains used as probiotics have been extensively characterized to produce an array of antimicrobial substances that contribute to their probiotic effect, including lactic acid, acetic
acid, formic acid, phenyllactic acid, benzoic acid, other organic acids, short-chain fatty acids,
hydrogen peroxide, carbon dioxide, acetaldehyde, diacetyl, acetoin, bacteriocins and
bacteriocin-like inhibitory substances, and others34. Bacteriocin production may be a critical
beneficial trait in probiotics as these compounds allow competition in the diverse microbial
community35. Bacteriocins are typically anti-microbial peptides released by a broad range of
bacteria during the stationary phase, inhibiting or killing similar or closely related bacteria.
Thus, bacteriocin production by probiotic strains may function in several ways to aid in host
immunity: facilitating a producer's introduction into an established niche, inhibiting invading
competitive or pathogenic strains, or modulating the microbiota composition 35. In addition,
anti-microbial molecules, both bacteriocins and others released from probiotic strains, are
believed to directly inhibit a range of pathogenic bacteria and aid in the competitive
exclusion of pathogens in the human microbiome 36.

1.2.4

Prebiotics

The idea of prebiotics originated from a study on carbohydrate consumption, which
positively impacted lactobacilli in the microbiota37; this study showed that diet could impact
and modify the microbiota. Prebiotics were described in 1995 as "nondigestible food
ingredients that beneficially affect the host by selectively stimulating the growth and/or
activity of one or a limited number of bacterial species already resident in the colon, and thus
attempt to improve host health" 38. The idea of supplementing diets to promote healthy
microbiomes has since focused on substrates targeted to Bifidobacterium and Lactobacillus
to build on the probiotic concept, though prebiotics may impact a much broader range of
beneficial microorganisms39. "Dietary prebiotics" are currently defined as "a substrate that is
selectively utilized by host microorganisms conferring a health benefit". This effect can
occur in the gut or elsewhere39.
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Prebiotics are mainly fructans (fructooligosaccharides (FOS) and inulin) and galactans
(galactooligosaccharides or GOS), as they specifically promote Bifidobacterium and
Lactobacillus but not pathogenic microorganisms40. Recently human milk oligosaccharides
(HMOs) have also been classified as prebiotics39,41,42, and consumption leads to higher levels
of Bifidobacteriaceae and Bacteroidaceae43. Unlike most dietary fibres, which promote a
broader range of microorganisms, prebiotics specifically enhance health-promoting
microorganisms.

1.2.5

Probiotic and prebiotic roles in the female urogenital tract

Consumption of probiotics can impact and modify the vaginal and bladder microbiota to
increase the level of commensal microorganisms 44, creating an unfavourable environment for
pathogenic bacteria45. Consumption of probiotics Lacticaseibacillus rhamnosus GR-1 and
Limosilactobaillus reureri RC-14* can help shift an unhealthy vaginal microbiota, leading to
significant increases in lactobacilli and reduction of pathogenic microorganisms while
actively taking an oral probiotic46. Prebiotics could be used to supplement probiotics, orally
or topically, and stimulate health-promoting species already present in the urogenital tract.
However, there is limited research on this combination in urogenital environments. Many
probiotic products include species of lactic acid bacteria (LAB), Bifidobacterium and
Lactobacillus. The probiotic activity of LAB in the vaginal environment is primarily due to
lactic acid excretion, which reduces pH (≤4.5), making it an inhospitable environment for
most pathogenic bacteria47. The production of antibacterial molecules such as bacteriocins
and hydrogen peroxide also makes them an ideal urogenital probiotic 35,48. Anti-microbial
molecules, both bacteriocins and others released from many lactobacilli strains, can inhibit
uropathogenic E. coli (UPEC) and reduce colonization of uroepithelial cells 48,49. Despite the
strong evidence to suggest a probiotic lactobacilli treatment can effectively limit urogenital
infections, there are very few targeted probiotic strains currently available and further clinical
studies are needed50.

*

Both bacteria have been reclassified from Lactobacillus rhamnosus GR-1 and Lactobacillus reureri RC-14137.
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1.3 Urogenital tract and diseases
1.3.1

Urogenital tract

The urogenital tract includes all organs in the reproductive and urinary system (Figure 1-1).
The normative female reproductive system includes the ovaries, fallopian tubes, uterus, and
vagina; the normative male reproductive system includes the testicles, duct system, seminal
vesicles, prostate gland and penis. The urinary system includes the kidneys, ureters, bladder,
and urethra. Females and males share the same urinary system, however, individuals with
shorter urethras (generally females) are at greater risk for bladder infections. 51

1.3.2

Functional anatomy of the urinary system

The upper urinary tract consists of the kidneys and ureters, while the lower urinary tract
contains the bladder and urethra18. Kidneys produce urine which travels through the ureters
to the bladder; when the bladder is full, the smooth muscles in the wall tighten and expel
urine through the urethra. Three main layers make up the bladder wall; urothelial, lamina
propria, and muscularis propria (detrusor) (Figure 1-1). The urothelium, the interior lining, is
a mucosal layer of transitional cells inside of the bladder. The lamina propria is a thin layer
of connective tissue containing blood vessels, nerves and glands, surrounding the urothelium.
Finally, the outer layer comprises three smooth muscle layers responsible for the contraction
and relaxation of the bladder.
The interior layer of the bladder was initially thought of as just a barrier to separate the
bacteria and interior bladder environment from the lower nerves and smooth muscle tissues.
It is now understood that the uroepithelial (urothelium) layer acts as a mechanosensory
conductor, transmitting physical and chemical signals from the bladder to the underlying
layers52. Uroepithelial cells express numerous receptors/ion channels that release
neurotransmitters into the lumen propria to excite the associated nerves and lower muscular
tissues53. Similarly, the urothelial cells can receive neurotransmitters from the nerves in the
lumen propria. As the bladder fills, it distends, stretching the urothelium and inducing the
release of neurotransmitters to regulate bladder contraction: ATP 52, acetylcholine (ACh)53
and nitric oxide (NO)54. The response to physical and chemical stimuli and release of
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signaling molecules by the urothelium demonstrates that it is vital in regulating nerve and
bladder function and not simply a barrier as it was once thought 55.

Figure 1-1. Female and male urogenital tract. The reproductive tract and urinary tract
together make up the urogenital tract. The urinary tract structures are the same regardless of
sex, and the male urethra is typically longer. The reproductive system is closely located to
the urinary tract, and the male urethra is part of both. The bladder wall constructing the
outside is divided into three distinct layers. Created with BioRender.com
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1.3.3

Bladder physiology

The bladder has two phases: urine storage and urine voiding. Bladder filling and urine
storage occur at low pressure while the bladder is relaxed and internal and external sphincters
are contracted. The sympathetic nervous system controls the storage phase; the
norepinephrine-releasing hypogastric nerve triggers relaxation of the smooth muscles and
engages the external sphincter56. The internal sphincter is constantly engaged and requires
internal pressure to releases56. As the bladder volume increases, the pressure triggers stretch
receptors in the urothelium, leading to nerve signaling bladder fullness and the need for
release52,56. Disruption to the storage phase often results in lower urinary tract symptoms,
including urgency, frequency, and urge incontinence56. Urine voiding requires simultaneous
contraction of the bladder and relaxation of the urethra and internal sphincter. When the
bladder is full, the urothelium signals the parasympathetic nervous system through ACh,
activating the parasympathetic motor neurons, which contract the smooth detrusor muscles,
causing increased pressure which releases the internal sphincter. Simultaneously the somatic
motor neurons inhibit the external sphincter allowing urine to pass through. ATP and other
neurotransmitters released by the nervous system, urothelial cells, or bacteria within the
bladder environment trigger smooth muscle contractions 57,58. Disruption of the voiding phase
is associated with hesitancy, weak stream, feeling of incomplete bladder emptying and posturination leakage56. In a healthy bladder, these phases allow controlled storage and release of
urine; however, physical and psychological disorders can disrupt signaling and lead to
bladder dysfunction and disease56.

1.3.4

Urinary tract diseases and disorders

Many conditions affect the bladder: bladder dysfunction, UTI, bladder stones, incontinence
(urge, stress, functional, overflow, mixed), interstitial cystitis, cystitis, neurogenic bladder,
OAB, cancer and asymptomatic bacteriuria. Many of these conditions present with similar
symptoms such as nocturia, frequency, dysuria, urgency, incontinence, hesitancy, straining,
weak stream, abdominal pain, intermittency, incomplete emptying and postmicturition
dribbling. Over half of individuals presenting with lower urinary tract symptoms are
misdiagnosed with UTI when they have OAB due to the high similarity of symptoms 59.
Bladder problems can affect both sexes or be specific to females or males. Individuals with
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uteruses can develop bladder problems due to shorter urethras, pregnancy and childbirth,
pelvic floor weakening, trauma or injury, or menopause. Individuals with prostates face
bladder problems associated with prostate health and disease. Both sexes experience an
increased frequency of bladder diseases due to ageing, infection, blockages of the urinary
tract, chronic coughing, constipation, and obesity2. Nervous system injury or disease,
including Alzheimer's, stroke, Parkinson's, multiple sclerosis, spinal cord injury, diabetes and
anxiety, can negatively impact and damage bladder nerves and muscles. With many urinary
tract diseases and disorders, there is a shift in the urinary tract microbiome 60. The urinary
microbiome changes observed with infection or insult could be addressed with probiotics,
prebiotics and dietary intervention to help revert the microbiome to a healthy state.

1.3.4.1

Overactive bladder

OAB is a complex of symptoms, UUI, frequency, and nocturia, characterized by unstable
bladder contractions. OAB is a disruption of the storage phase due to the involuntary
contraction of the smooth muscles of the bladder. The predominant symptom of OAB is UUI,
the sensation to urinate regardless of bladder fullness 1. This condition is frequently
undertreated and underreported1. Globally, OAB affects 1.5-36.4% of populations, 10% in
Canada61, with prevalence depending on age and sex62. The economic burden of OAB in
America in 2020 was $82.6 billion and is estimated to increase as the population ages 57.
Individuals suffering from OAB often have decreased quality of life, lower work
productivity, and higher anxiety and depression63.
There are several treatment options for OAB, including fluid management, behavioural
modification, bladder training, pelvic floor exercises, drug therapy, neuromodulation and
surgery; however, treatments are often unsatisfactory64. The goal behind treatment is to
improve the quality of life for the patient as there is no cure, only symptom reduction.
Behavioural therapy is the most common course of treatment followed by pharmacological
administration; mainly antimuscarinics65 which limit ACh binding to muscarinic receptors51.
Unfortunately, there is no truly effective drug treatment; those available have very low
efficacy, and the side effects generally deter long-term use64.
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Despite active research and drug development, there has been limited improvement in
treatment. There is no set definition of 'failure' or 'success' in a patient suffering from OAB,
as how the treatment impacts the patient's quality of life varies greatly and cannot be
standardized. Responses to treatments are also widely impacted by comorbidities, drug
metabolism, concurrent therapies and more. These factors are not always obvious and make
it hard to determine if a treatment will be successful in an individual patient. A greater
understanding of what causes the symptoms could result in new and more successful ways to
address OAB.

1.3.4.2

Urinary tract infections

UTIs are among the most common infectious conditions globally, mainly impacting females
and the elderly – UTI prevalence increases with age. There are approximately 150 million
cases annually worldwide, with 50% of females and 5% of males contracting a UTI in their
lifetime2, and they cost over $6 billion world wide 66. Most commonly, UTIs are caused by
bacteria, predominantly UPEC strains67,68. Risk factors for UTIs include sexual intercourse,
previous UTIs, new/multiple sexual partners, urethral length, certain birth control types, and
menopause69,70. Many are caused by the ascension of pathogens from the rectum along the
perineal skin and then through the vagina or directly up the urethra to the bladder.
Symptomatic UTIs present with malodorous urine, abdominal pain, dysuria, frequency and
urinary urgency71.
There are four different types of UTIs, dependent on infection location: urethritis (urethral
infection), cystitis (lower urinary tract), urethritis (ureter infection due to blockage or
infection migration), and pyelonephritis (an infection spread to the kidneys or from a urinary
tract blockage resulting retrograde flow of infected urine). An infection involving the urethra
and bladder is termed a lower UTI, while an infection of the ureters or kidney is an upper
UTI. Most UTIs are uncomplicated lower tract infections, occurring in otherwise healthy,
non-pregnant, pre-menopausal individuals with a normal functioning urinary tract.
Complicated UTIs are associated with catheters, blockages, and functional abnormalities,
resulting in increased colonization and decreased efficacy of therapy. Recurrent UTI occurs
after a previously documented infection has been resolved, when an individual has two or
more infections in 6 months or three or more infections in 12 months 72,73. Healthcare-

12

associated UTIs are the most common form of hospital-acquired infections 72 and lead to
more prolonged hospitalizations, increased morbidity and mortality69.
A UTI is diagnosed with clinical presentation of symptoms and urine microbial evaluation.
To identify the causative pathogen and suggest an ideal treatment both urinalysis and urine
culture with sensitivity should be used; however, immune markers in urine alone are often
used to identify infection in clinic74. Treatment is determined based on infection and severity
of symptoms, as well as any predisposing host factors. Uncomplicated and complicated UTIs
are often treated with hydration and antibiotics, removal of any obstructions in the urinary
tract, and catheter removal or replacement74,75. Antibiotic treatment is often empirical before
proper diagnosis had been acquired. The drug selection should depend on the infection
location (urethra, bladder, ureter or kidney), which pathogen is believed to be responsible for
the infection, and if there is any drug resistance74–76. The most commonly used antibiotics are
trimethoprim/sulfamethoxazole, nitrofurantoin, fosfomycin, cephalexin and ceftriaxone.
Frequently, fluoroquinolones are prescribed as a first choice instead of being reserved for
more serious cases.
The majority of orally ingested antibiotics are highly concentrated in the urine, making them
highly effective at clearing bacteria from the lower urinary tract. When kidney tissues are
infected, antibiotics that can penetrate the tissue are needed 77. Though antibiotics effectively
treat UTIs, they can disrupt the vaginal microbiome for up to 6 months resulting in a reduced
Lactobacillus population and increased uropathogenic presents in the urethra 78. Individuals
who experience recurrent UTIs often require suppressive antibiotic therapy, long-term
prophylaxis or post-coital prophylaxis. Increased risk of side effects associated with longterm antibiotic use makes this a less ideal treatment 73. Intravaginal estrogen can be used in
postmenopausal individuals to reduce recurrent UTI risk which is associated with thinning
vaginal epithelium and a tendency for dysbiosis73. The research on non-antibody prophylaxis
options is limited; however, Lactobacillus probiotics79,80, methenamine81, cranberry
polyphenols82 and D-mannose83–85 are sometimes added to treatments and can be beneficial
in the prevention of UTI.
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1.3.5

Urgency urinary incontinence

Urinary incontinence (UI), defined as involuntary loss of urine86, is a common symptom
associated with bladder and pelvic floor dysfunction. There are three primary types of UI:
stress UI (SUI), urgency UI (UUI) and mixed UI (both SUI and UUI); SUI is the involuntary
loss of urine on effort or physical exertion or on sneezing or coughing (activity-related UI);
UUI is the involuntary loss of urine associated with urgency86; urgency is the complaint of a
sudden compelling desire to pass urine which is challenging to control 87. UUI is potentially
caused by physiological disruption of the detrusor muscle in the bladder wall and/or muscles
in the pelvic floor, which leads to leaking and the urgency sensation 88. Abnormal
neuromuscular signaling and/or function of the bladders storage and voiding phase also leads
to UUI; this can be chronic and is poorly understood88. This symptom can occur in males and
females. In males, it is more frequently associated with prostatic enlargement or damage than
muscle dysfunction as in females88. The symptom is frequently defined as only present in a
'non-infected’ bladder87; however, UUI can result after or during a UTI61, meaning it can be
seen in an infective environment16,17,89. The specific global impact and economic burden of
UUI is hard to ascertain due to the overlap of UI conditions and OAB patients; however,
millions of individuals suffer the effects of UUI, and the economic burden is substantial 62. As
the current population ages, there is a projected increase in UUI prevalence and UUI
associated comorbidities62.
Treatment of associated conditions often address UUI. If treatment does not impact the UUI
symptom, it could be considered chronic and require further lifestyle changes or surgery90.
With chronic UUI, the goal tends to be symptom reduction rather than complete resolution;
treatment to decrease symptoms is unique to the patient and their lifestyle 88. Similar to OAB,
treatments target lifestyle changes, timed voiding, bladder training, weight loss, and fluid
optimization91. There are pharmacological treatments for UUI, however, they fail or are
unsatisfactory in approximately half of the patients65. Lifestyle changes often give the best
result when dealing the chronic UUI, as long as the patient is willing to work with their
clinical team88. Microbiota disruption is commonly found in individuals suffering from UUI,
suggesting bacteria may play a significant role89. Further research is needed to understand the
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overlap and role that UUI plays in UTI and OAB and the role of microorganisms in UUI
symptoms.

1.3.6

Establishment of UTI

Uncomplicated UTI is predominantly caused by E. coli, Klebsiella pneumoniae, Proteus
mirabilis, Enterococcus faecalis and Staphylococcus saprophyticus92. As noted above,
bacteria are introduced to the urinary tract from the rectum, peritoneum, sexual intercourse,
or some forms of birth control (Figure 1-2). Adherence to host cells through flagella and pili
appears important for the establishment of bacterial infection 93. Upon introduction to the
urinary tract, bacteria migrate up the urethra towards the bladder. At the bladder, bacterial
flagella, pili and adhesins promote colonization and bind directly to the bladder epithelium.
During infection, UPEC strains can reside in fusiform vesicles within urothelial cells to avoid
elimination with voiding and re-emerge during distention of the bladder 55. Host inflammatory
responses to infection of the urinary tract include neutrophil infiltration to clear extracellular
bacteria. However, bacteria can evade the immune response through biofilm formation, host
cell invasion and morphological modification. Immune evasion allows further bacterial
multiplication and infection progression. Bacteria produce toxins and proteases to damage
host cells and release nutrients which promote bacterial survival 92. Damaged bladder
epithelial cells will shed off, exposing bacteria hiding in the wall and aiding in bacterial
clearance during voiding. Cell shedding, in part, explains how some UTIs self-resolve
without antibiotics. When the bladder distends with urine and during storage, remaining
bacteria thrive in the nutrient-rich environment. From the bladder, bacteria can migrate up
the ureters towards the kidneys92, where they can infiltrate and damage the renal epithelium
and easily cross the tubular epithelial barrier and access the bloodstream, causing bacteremia.
In a complicated UTI, the introduction of bacteria and urethra migration are similar;
however, the bladder, ureter or kidney must be compromised. Catheter placement and stones
induce a host response, resulting in fibrinogen accumulation, ideal for fibrinogen-binding
proteins expressed by pathogens92. When there is an obstruction, biofilms on medical devices
or epithelia shield bacteria from neutrophils, antibiotics, and other stressors while promoting
growth92,94. Biofilm formation is common in uropathogenic bacteria, especially in
complicated UTIs associated with catheters and other obstructions 2,95.
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Several virulence factors contribute to UPEC strains effectively establishing a UTI.
Expression of type 1 pili plays a role in binding to the epithelium with tip adhesin FimH,
binding to mannose epitopes and paucimannosdic glycans conjugated to uroplakin Ia. Once
bound, bacteria can invade cells96, where they multiply to form intracellular bacterial
communities, avoiding host immune responses (outside and inside the cell), and antibiotics 96.
Upon bursting from the cell, the pathogens invade neighbouring cells and repeat the process.
UPEC can also establish quiescent intracellular reservoirs, 4-10 non-replicating bacteria
encased in F-actin, which can remain viable for months in lower transitional cells allowing
reinfection92,96. While in the bladder, UPEC releases molecules to promote its survival and
control its environment. Toxin α-hemolysin lyses cells through pore formation, causing
shedding and releasing host nutrients and iron; siderophores scavenge iron and allow uptake
into the bacteria92,96. Cytotoxic necrotizing factor 1 induces host cell anti-apoptotic and prosurvival pathways to prevent apoptosis and further bacteria colonization 92,96. Extracellular
UPEC filamentous morphology can be modified, making the bacterium more resistant to
neutrophil killing86. In the kidneys, pyelonephritis-associated p-pili bind globosidecontaining glycolipids on renal tissues, and the PapG adhesion tipping the pili modulates the
host immune response to prevent opsonization and clearance. Cell adhesion, toxins, immune
evasion, and intracellular colonization make UPEC strains ideal urinary pathogens.
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Figure 1-2. Establishment of urinary tract infection. Uncomplicated UTI initiated after
contamination of the periurethral area (1), colonization of the urethra and migration to the
bladder (2). Expression of pili and adhesins allows colonization of urothelium umbrella cells
(A). Bacteria work to evade immune response through host cell invasion (A-C) and biofilm
formation (3). Adherent bacteria invade cells and are expelled back into the lumen or escape
from the vesicle into the cytoplasm (B). Bacteria can replicate in the cytoplasm, burst out of
the cell, invade adjacent cells, or create quiescent intracellular reservoirs that may seed
further UTIs (C). Host inflammatory responses, including neutrophil infiltration (4), work to
clear extracellular bacteria. If bacteria persist, they can produce toxins to damage host cells
releasing nutrients to promote survival and ascension to the kidneys (5). Kidney colonization
and tissue damage initiated by bacteria (6), untreated this can progress further to bacteremia
(7). Created with BioRender.com
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1.3.6.1

Addressing bacterial infection

As previously described, antibiotics are most frequently used to treat UTI of which most are
broad spectrum. There are other methods that have been devised to reduce recurrent UTIs.
These include modulation of host immune responses, interfering with UPEC adhesion to
urothelial cells, preventing and disrupting biofilms, and limiting invasion into host cells.
Several vaccines under development target UPEC specifically, allowing a heightened
adapted immune response against the O-antigens97, siderophores98, surface antigen YncE99,
and E. coli extract100; though currently, none are available for patient use. Estrogen
supplementation targets vaginal epithelial thinning and can lower recurrent UTI rates in
postmenopausal women96. Modification of the bladder pH with organic acids and vitamin C
has a bactericidal effect further enhanced with methenamine which hydrolyzes formaldehyde
and ammonia81,96. Polymeric phenolic proanthocyanidins (isolated from cranberries) can
reduce P-fimbrial adhesion in vitro, but so far, cranberry extract studies do not support
consistent UTI reduction96. Reducing adhesion by targeting and binding FimH with high
levels of D-mannose in the urine prevents urothelial binding in vitro84,96, but again strong
evidence is lacking that this can be effective clinically. Restoration of the urinary microbiota
though supporting lactobacilli could be beneficial 21. Probiotic strains show promise in
reducing pathogen loads, stimulating the immune system and modulating the environment
with hydrogen peroxide, surfactants, bacteriocin-like molecules and anti-adhesion
molecules23,36,79,97,101,102. These treatments could potentially be used in conjunction with an
antibiotic regimen to help treat and prevent UTIs.

1.3.7

Disrupted urogenital microbiomes and bladder disease

It is now appreciated that UUI and UTI are associated with imbalances in the urogenital
microbiota89,103,104. Current treatments were not designed to protect the beneficial microbes
nor to appreciate significant differences between the microbiota of healthy individuals and
those with urological disease89,103.
Comparisons of the urinary microbiome of women with UUI to those without showed a
significant difference in abundance and frequency of bacteria 89. In women with UUI,
Lactobacillus abundance was lower, and L. gasseri was more common than L. crispatus89.
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Gardnerella is associated with a disrupted microbiota, commonly found in women with
bacterial vaginosis and individuals with UUI, but not in healthy individuals 89. Uropathogenic
species were also more frequently found in UUI patients 89. However, it is unknown if this
shift in microbiota contributes directly to UUI or is a result of the condition. The urogenital
microbiota is also altered in patients with UTI and recurrent UTIs 59,79. Not only do pathogens
disrupt the microbiome, so too do antibiotic treatments resulting in pathogenic bacteria
lingering for months78. More research is needed to understand the differences between
urinary microbiomes in healthy and infected individuals, which could lead to better
therapeutic options.

1.3.8

Impact of eATP in the bladder

It has long been recognized that ATP is a universal intracellular energy source involved in
cellular respiration, metabolism and cellular processes. Beyond its role as an energy storage
molecule, eATP is a known purinergic neurotransmitter6 that can modulate host nervous
systems, host immunity, and acute and chronic inflammation 105,106. Higher ATP levels are
associated with several human bladder conditions, including UTI and OAB 3,107,108. For over
50 years UTI has been diagnosed by rapid test for ATP in urine 3. The UUI associated with
OAB could be triggered by high ATP concentrations stimulating the bladder epithelium at
lower volumes1. ATP plays a crucial role in the bladder's neural and motor function through
purinergic signaling6. Bladder stretching stimulates urothelial-derived ATP release, and as
the bladder fills, the ATP levels rise, with the highest concentrations observed in a full
bladder109. Uroepithelial and sub-urothelial cells purinergic (P2) receptors, ionotropic P2X
and metabotropic P2Y receptors are responsible for urothelial ATP release in response to the
increased levels of eATP110–113. In a healthy bladder, eATP binds P2X3 receptors to alert the
bladder of fullness. In a patient with UUI, ATP levels in a reduced volume bladder are
significantly higher and could trigger the urgency sensation 109. Higher ATP concentrations in
disordered bladders can impact bladder function, increasing urination frequency, inducing
pain and full bladder sensations with lower volumes4,114. Blocking or knocking out the P2X
receptor can reduce bladder symptoms caused by increased ATP levels 114,115. Despite this,
current treatments do not use ATP reduction or P2X blocking to address bladder conditions.
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1.3.9

The role of calcium in the bladder

Calcium (Ca2+) ions play a regulatory role in the contraction of the smooth detrusor muscle in
the bladder wall116. In the urothelium, transient receptor potential (TVR) channels (TRPV1
specifically) and purinergic receptors control intracellular Ca2+ concentrations and are
sensitive to neurotransmitters such as ATP 117. Neurotransmitter release and cellular processes
can be regulated through Ca2+ influx and blocking ion channels inhibits neurotransmitter
release. When the action potential is reached at a nerve terminal, voltage-dependent Ca 2+
channels open, and the greater extracellular concentrations cause Ca 2+ to enter the terminal.
Following Ca2+ influx, there is a rapid release of neurotransmitters into the surrounding area.
Purinergic receptors are triggered to release ATP by increased eATP levels, and with greater
ATP there is an associated increase in intracellular Ca2+ leading to cellular depolarization (an
excitatory phase)118. As bladder Ca2+ increases, sub-urethral parasympathetic postganglionic
nerve terminals release neurotransmitters ACh and ATP, exciting cholinergic muscarinic
receptors and triggering detrusor contraction and micturition 118. Over activation of these
pathways at lower urine volumes may be related to urgency conditions 116. Potentially, Ca2+
channel antagonists, such as NO119, or GABA5 could be used to suppress and regulate
contractions associated with increased urinary ATP.

1.3.10

Bacterial release of neurotransmitters to regulate their
environment

The gut microbiota interacts with the host by releasing neuroactive molecules such as γaminobutyric acid, serotonin, histamine, dopamine and norepinephrine 120. These and other
neurotransmitters can modify gut physiology and impact the nervous system and brain. Since
the discovery of the urogenital microbiota, there has been minimal research on host-bacterial
interactions; however, bacteria known to release neurotransmitters are found in the urogenital
tract. The lower urinary tract connects to the pelvic parasympathetic nerves, lumbar
sympathetic nerves and pudendal nerves117. Purinergic neurotransmission at these nerves can
control smooth muscle contractions, and increased purinergic function can lead to unstable
bladder conditions. Thus, neuroactive molecules produced by urinary microbes could
similarly impact the bladder environment by interacting with the host nervous system.
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Several studies have shown that bacteria release ATP into the extracellular environment
during exponential and log phase growth121,122. As noted above, bacteria can also reduce
eATP levels during growth5,122. During infection, the higher ATP levels in the urine can be
attributed to bacteria, however there is also host release of ATP in response to bacterial
ATP123. As a crucial lower urinary tract neurotransmitter, bacterial ATP could control
smooth muscle contraction similarly to host ATP. Uropathogenic E. coli IA2 and
Gardnerella vaginalis 14018 can trigger Ca2+ influx and smooth muscle contractions of
myofibroblasts through purinergic signaling via extracellular ATP release 5. Compared to E.
coli IA2, G. vaginalis 14018 releases significantly more ATP5 which could contribute to
urgency in OAB patients who have an uninfected bladder. However, certain lactobacilli can
reduce ATP levels in media supplemented with bacterially relevant concentrations.
Additionally, Lactobacillus supernatant can reduce smooth muscle contractions triggered by
uropathogenic bacterial supernatant5.
The release of extracellular ATP may be associated with bacterial cellular respiration. A
study found that bacterial mutants without cytochrome bd oxidase release less ATP
compared to wild-type124. Increased ATP release is seen in E. coli which has up to six bdtype oxygen reductases, compared to lactobacilli which may have only one 124. The difference
in oxygen reductases suggests that they could play a role in the level of ATP bacteria can
release. Another study demonstrated that glucose is essential for ATP secretion 125. Taken
together, these studies imply a potential causal link between cellular respiration, nutrient
availability and ATP release/uptake.

1.3.11

The potential role of eATP released by bacteria during infection,
and detrusor muscle control in the bladder

The role of ATP in bladder contraction and urgency symptoms has been well documented
and understood. However, prior to work done in our lab, it has not been related to the
urogenital microbiota. The association between bacteria releasing and uptaking ATP during
growth, the known neuron interaction between microbiome and host, and the bacterial levels
of ATP in urine suggest that bacteria could utilize ATP to modulate the bladder environment
during infection. During UTI, uropathogenic bacteria could release neurotransmitters (ATP)
to target the urothelium purinergic receptors. Bacterial ATP stimulates the release of host
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ATP, increasing Ca2+, creating an energy potential that releases ACh and ATP in suburothelial layers to target detrusor receptors and causes urgency and bladder contractions at
low urine volume.

1.4 Potential therapeutic use of lactobacilli against eATP
1.4.1

Benefits of lactobacilli

Lactobacilli play a crucial role in maintaining a healthy urogenital tract. When disease
occurs, there is generally a reduction or shift of the dominant Lactobacillus species; with this
change, the host loses the commensal benefits previously provided. The ability of lactobacilli
to protect the host is multi-factorial126–128.
In addition to previously identified probiotic benefits, lactobacilli may play a role in reducing
ATP from the environment. When L. crispatus ATCC 33820 was co-cultured with
uropathogenic E. coli IA2, lower levels of eATP were found, suggesting consumption of
eATP5. The high levels of ATP released by E. coli IA2 appear to cause smooth muscle
contractions through purinergic signaling, and L. crispatus ATCC 33820 supernatant can
decrease these contractions5. Furthermore, Lactobacillus has been shown to have a cytotoxic
effect on E. coli in vitro, suggesting that it produces a bacteriocin-like molecule to target and
inhibit or kill the pathogen7,8.

1.4.2

Host introduction of lactobacilli and prebiotics

The ability to manipulate the urogenital microbiota and restore it to one associated with
homeostasis is not a simple task. Introduction of a probiotic strain could be achieved via
topical application (to the external distal urethra and vagina), oral consumption or a
catheter46,129,130; a non-invasive method is preferred. Lactobacilli strains for urogenital tract
health should be selected based on their ability to survive and grow at this interface and in
urine, plus properties that allow them to interfere with pathogenic bacteria 131. Both L.
rhamnosus GR-1 and L. fermentum RC-14* are good candidates46,130,132, though others likely

*

Reclassified to Lacticaseibacillus rhamnosus GR-1 and Limosilactobaillus reureri RC-14137.
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exist. The addition of an appropriate prebiotic, such as lactulose 133, may also promote
recovery of the lactobacilli in the vagina and stimulate the probiotic strains 46,84,134–136.

1.5 Rational and hypothesis
In summary, ATP plays a role in both healthy and diseased bladder states. Uropathogenic and
bacteria associated with urogenital disorders release ATP during growth. Consequently, more
studies are required on regulation and reduction of ATP in the bladder to address symptoms
and provide relief to UTI and UUI patients. The ability of lactobacilli to reduce ATP might
provide a means to limit pathogenic impact on the host and urogenital microbiome. It is
hypothesized that Lactobacillus spp. can modulate extracellular ATP levels released by
bacteria in a urinary environment. It is hoped that this thesis will add to our understanding of
the role that eATP plays in urogenital infections and provide a path towards novel
approaches to treatment and disease management.
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Chapter 2

2

Bacterial release and consumption of ATP during growth

This chapter focuses on the adenosine triphosphate (ATP) levels released and taken up by
pathogenic and commensal bacteria during growth. The goal was to understand which
microorganisms can produce, sequester, or regulate extracellular ATP (eATP). This research
also identifies the potential of eATP for uropathogenic swarming bacteria to utilise and
follow as a chemoattractant.
A portion of the bacterial ATP screening work was completed by undergraduate student
Jennifer Chen during her fourth-year thesis project. Undergraduate student Vibusan
Shanthirasegaram completed the directional growth assays during his fourth-year project. Dr.
Jeremy Burton supervised both, and their research and experiments were directed with my
assistance.

2.1 Abstract
ATP is a crucial energy source that is utilized by all living organisms. It is an energy storage
molecule that powers intracellular processes. Several bacteria have been shown to secrete
ATP extracellularly, modulating the host environment as a neurotransmitter and potentially
representing a virulence factor. In this study, ATP release during growth was assessed in 27
bacterial strains, including commensal, uropathogenic and other pathogenic bacteria. In
addition, the swarming patterns of uropathogenic Proteus mirabilis were assessed in the
presence of ATP and bacterial supernatants, to understand if bacterial eATP could impact
another organism in the environment. The results showed that eATP concentrations were
strain-specific and varied significantly within a species. Pathogenic organisms generally had
greater levels of ATP release compared to commensals tested. The level of eATP increased
and peaked during log-phase growth, then decreased in the stationary phase in Escherichia
coli IA2 and Lactobacillus crispatus ATCC 33820. In addition, there was an observable
directional growth change by P. miarbilis associated with ATP and bacterial supernatant.
This study suggests that eATP release is specific for each bacterial strain and could
supplement nutrients in the stationary phase. Greater concentrations of eATP in pathogens
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support the idea that bacterial eATP can modulate the environment and represent a novel
virulence factor.

2.2 Introduction
All living organisms require and utilize ATP as an energy source and storage molecule. The
energy storage molecule is generated through cellular respiration and can be used to power
cellular functions necessary for survival, growth and replication. It is not yet fully understood
how bacteria release and take up ATP during growth 1–3. Generally, eATP concentrations
peak around exponential phase growth then reduce in stationary phase 1–3. Both intracellular
and eATP levels are well documented in E. coli, with significantly higher intracellular levels
of 1-5 mM. The amount of intracellular ATP changes in response to environmental and
physiological pressures on the bacterium4–8. Pathogenic as well as commensal species can
release ATP, though higher levels are observed in pathogenic bacteria 3,9,10. The amount of
ATP released may be linked to glucose availability and cellular respiration 3,11. Beyond the
role played in bacterial survival and growth, eATP is interacting with the host environment.
Host or bacterial ATP can act as a neurotransmitter, triggering a range of signals in
humans12. In the gastrointestinal tract, bacterial eATP can modulate the environment by
promoting bacterial-host cross-talk, controlling immune cell differentiation, and mediating
inflammation9,13. In the bladder, ATP concentrations rise as urine volume increases, which
causes bladder distention and eventually triggers muscle contractions, bladder voiding and
micturition14–16. In human urinary and gastrointestinal tracts, eATP signals through
purinergic receptors P2, specifically P2X and P2Y 17–20; these responses can be reduced by
blocking the P2X receptor in environments with higher eATP concentrations 15,21. These
findings suggest that bacteria could use ATP to alter their environment during growth, acting
either as a virulence factor or stimulating host-bacterial communication in commensals.
The mechanism of bacterial ATP secretion is unknown; however, several methods of
secretion are observed in eukaryotic cells and other microorganisms. Eukaryotic cells release
ATP through pore-forming channel-mediated release, active vesicle-mediated exocytosis and
non-specific release22. Fungi such as Candida albicans secrete ATP via conductive channels
and are histatin5 dependent, which leads to the death of neighbouring C. albicans cells23.
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Saccharomyces cerevisiae releases ATP via MCD4P glucose-dependent membrane protein
though vesicular trafficking initiated by ATP uptake into the Golgi compartment 24. In S.
cerevisiae, similar to E. coli, eATP concentrations are linked to glucose availability11,25.
Cytochrome bd oxidase is vital to ATP secretion in Salmonella enterica; as in E. coli,
mutants lacking bd oxidase subunits had significantly reduced eATP levels compared to
wildtype3. The cytochrome bd oxidase creates a proton motive force by pumping protons
over the inner bacterial membrane, which catalyzes the final step in cellular respiration. The
reduction in ATP release by E. coli with lower glucose availability and cytochrome bd
oxidase mutants suggests that glycolysis and respiration are linked to higher ATP release
than fermentation. Furthermore, this demonstrates that E. coli can build up ATP
intracellularly and release it with functional respiration. Potentially, excess ATP can be
released into the environment for storage until later, when intracellular levels are depleted.
None of the previously identified ATP release mechanisms have been observed in bacteria,
and the necessary genomic pathways are mostly absent. However, there are several proposed
mechanisms through which ATP could be released and taken up by bacteria: porins,
mechanosensitive channels, outer membrane vesicles, efflux pumps/secretion systems or
lytic mechanisms during growth26. General porins in the outer bacterial membrane could
facilitate eATP uptake passively or by a gradient into the cell periplasm where there is
constant ATP, though none have been identified. Mechanosensitive channels secrete ATP
and other small metabolites when bacteria are exposed to hypertonic osmotic shock 27,28;
however, this has not been observed in unstressed bacterial growth. Finally, outer membrane
vesicles play a known role in bacterial pathogenesis and contain ATP, which can be released
extracellularly, though this is not fully understood 29.
The role that outer membrane vesicles play in eATP fluctuations is unclear. There is a steady
amount of ATP in the periplasmic space which could be from production or uptake from the
periplasm. An outer membrane vesicle could facilitate ATP transport from the periplasmic
space to the extracellular environment26,29. During cell division and cell lysis ATP could also
leak out, leading to increased eATP concentrations post log-phase growth 26. There could also
be unidentified efflux pumps or secretion systems in bacterial membranes specific to ATP 26.
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In addition to releasing ATP, several bacteria can consume ATP from their environment.
When media is supplemented with ATP, E. coli K-12, S. enterica SE2472, L. crispatus
ATCC 33820, and Lactobacillus gasseri KC-1 can reduce or eliminate the supplemented
concentration during growth3,10. After presumed uptake, ATP can be found in the periplasm
where it is hydrolyzed29. Hydrolysis of ATP could feasibly occur on the outer membrane3, or
there could be another unidentified mechanism of consumption. There is a steady ATP
concentration in the periplasmic space, which is hydrolyzed in a linear eATP-dependent
manner29. Assuming ATP enters into the bacterial periplasm, there is no known mechanism
by which it could be transported into the cytosol or transported out from the cytosol 26.
Further research is needed to understand how bacteria reduce eATP concentrations and the
cellular machinery used in this process.
The bacterial release of ATP may be a virulence factor that helps to modulate the
environment during infection. Bacterial eATP impacts the host through immune cell
modulation9, bladder contraction control10, induction of host cell ATP release10,29, induction
of pain15,19, and triggering acute and chronic inflammation13,30. Biofilm formation, a common
uropathogenic virulence factor especially in complicated UTIs 31,32, is promoted by ATP33–35.
Intracellular ATP is used as a nutrient source and a signaling molecule during biofilm
formation1,34. Similarly, increased eATP levels could be a nutrient source or bacterial
signaling molecule. A common uropathogen, P. mirabilis, forms biofilms on catheters
allowing the infection to progress with limited host interactions 36. Unique swarming motility
of P. mirabilis could facilitate migration from the periurethral region up the catheter surface
to the bladder37. Higher levels of eATP released by bacteria or the bladder could aid in P.
mirabilis infection establishment. Biofilm formation can be reduced in vitro by decreasing
environmental ATP with the application of apyrase38 (a calcium-activated enzyme that
catalyzes the hydrolysis of ATP to yield AMP and inorganic phosphate). In the bladder, high
levels of eATP can trigger Ca2+ influx39; application of apyrase could potentially lower the
eATP levels and their negative impact on the host.
Our lab has shown ATP enhances the growth of E. coli IA2 and L. crispatus ATCC 33820 in
media, leading to a reduction in eATP10. This suggests that a commensal bacterium which
consumes ATP could be introduced to the bladder, or a species that is already present could
be promoted to reduce pathogenic eATP, thus contributing to a healthy urogenital tract. Host
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purinergic receptor activation by bacterial eATP could play a vital role in virulence, and the
increased eATP might act as a signaling molecule to other microorganisms or as a nutrient
source.
The discovery of bacterial ATP secretion is relatively recent 1, and there has not been much
research into a release mechanism or host interactions. However, there has been a recent
increase in studies on bacterial eATP and its role in growth 13. Increased eATP concentrations
are associated with urinary tract infection (UTI) and overactive bladder (OAB), but little
research has been done to understand the role of pathogenic bacteria in these
conditions10,15,16,40–42. The urogenital microbiota, ATP release and bacterial interaction has
been overlooked by current UTI and OAB treatment methods. The fact that microbiota
dysbiosis is associated with these conditions 43–45 should factor into novel treatment
approaches in the future.
Overall, bacterial eATP may significantly impact the host environment and neighbouring
microorganisms; however, the mechanism of release, specific host impacts, and uptake
mechanism have not been elucidated. Understanding which bacteria, both commensal and
pathogenic, can produce or sequester eATP will contribute to a greater comprehension of the
role eATP plays in bacterial growth and infection. In this chapter, uropathogenic and
commensal bacteria isolated from the human urogenital tract and others will be screened to
assess the release and sequestration of ATP. Additionally, the impact of ATP and bacterial
ATP in supernatant on uropathogenic P. mirabilis 296 swarming will be investigated to
understand if ATP can influence its growth pattern.

2.3 Materials and methods
All bacteria were maintained on agar: E. coli IA2 and P. mirabilis 296 on Lysogeny broth
agar [LB; Difco, MD]; Lactobacillus gasseri KC-1, L. crispatus ATCC 33820 on de Man,
Rogosa and Sharpe agar [MRS, Difco, MD]. All other bacteria were maintained on their
preferred media (Table 2-1). All bacteria were grown at 37°C, and anaerobic species were
grown in an anaerobic jar.
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2.3.1

Evaluation of eATP production in liquid media from an overnight
culture

To screen eATP release single colonies of bacteria were inoculated into media and incubated
overnight aerobically and anaerobically (Table 2-1). Several media types were used; de Man,
Rogosa and Sharpe [MRS; Difco, MD], lysogeny broth [LB; BD Difco, MD], brain heart and
yeast extract [BHYE; BD Difco, MD], and vaginally defined media with peptone (VDMP) 46;
as each contains different levels of ATP which could impact the study. For example, MRS
has high levels of ATP, which impact screening and bacterial uptake. Bacteria were grown in
3 mL of media aerobically and anaerobically at 37°C overnight. Drop plates were used to
calculate colony forming units (CFU) of each bacterium. The liquid culture was centrifuged
at 6000 × g for 10 minutes, then 100 µL of cell-free supernatant was collected and placed in
an opaque white 96-well plate. If needed, the plates were frozen at -80°C, then thawed to
room temperature for 45 minutes before ATP quantification. The established BacTiter-Glo
microbial cell viability assay [Promega, WI] was used according to the protocol to quantify
ATP contents with a luminometer [Biotek, VT]. With each screening, a media-only control
and media-specific ATP standard curve were used to normalize ATP levels. All ATP
concentrations were then related to bacterial CFU for comparisons between strains.
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Table 2-1. Bacterial strains screened for eATP production after 18 hours of growth
Bacterial Strain

Medium

Origin or Relevant Characteristics

E. coli UTI89

LB

Patient with an acute bladder infection

E. coli DSM 103539

LB

Asymptomatic bacteriuria isolate

E. coli Nissle 1917

LB

Feces of German soldier in 1917

E. coli IA2

LB/VDMP

Patient with a urinary tract infection

E. coli K-12

LB

Patient with diphtheria in 1922

E. coli CFT073

LB

Patient with pyelonephritis

P. mirabilis 296

LB

Patient with a urinary tract infection

S. marcescens db11

LB

Insect isolate

E. faecalis ATCC 33816

LB

Type strain

B. subtilis 168

LB

Mutagenized B. subtilis Marburg

S. anginosus T-29

BHYE

Group F Streptococcus

S. pyogenes FF22

BHYE

Group A Streptococcus

S. uberis ATCC 27958

BHYE

Type strain, a bovine udder infection

S. pyogenes 71-679

BHYE

Group A Streptococcus

L. lactis subsp. lactis T-21

BHYE

Group N Streptococcus

S. pyogenes 71-698

BHYE

Group A Streptococcus

S. pyogenes W-1

BHYE

Group A Streptococcus

S. dysgalactiae subsp. equisimilis T-148

BHYE

Group C Streptococcus

S. pyogenes MGAS8232

BHYE

Group A Streptococcus

S. pyogenes NGAS979

BHYE

Group A Streptococcus

L. crispatus ATCC 33820

MRS/VDMP

Type strain, eye isolate

Limosilactobacillus reuteri RC-14

MRS

Vagina of a healthy individual

Lacticaseibacillus rhamnosus GR-1

MRS

The urethra of a healthy patient

Lacticaseibacillus rhamnosus GG

MRS

Feces of a healthy patient

Lactiplantibacillus plantarum LP39

MRS

Type strain, fermented food

MRS

Type strain

MRS

Type strain, dairy products

Lacticaseibacillus paracasei ATCC
25302
Lacticaseibacillus casei 393

45

2.3.2

ATP quantification

Following the manufacture's protocol, a luminescent assay kit (BacTiter-Glo microbial cell
viability assay [Promega, WI, G8230]) was used to quantify eATP released by the bacteria
into the supernatant. BacTiter-Glo microbial cell viability assay has already successfully
been used to assess various bacterial strains, including L. crispatus ATCC 33820 and E. coli
IA2, in a variety of media10. Luminescence was measured with a microplate reader
(Synergy™ H4 Hybrid Multi-Mode [BioTek, USA]) from which ATP could be quantified.

2.3.3

Evaluation of eATP from E. coli IA2 and L. crispatus ATCC
33820 over 24 hours

Both E. coli IA2 and L. crispatus ATCC 33820 were grown in VDMP anaerobically at 37°C
for 24 hours. Samples were collected every 30 minutes for the first six hours and every hour
proceeding for 24 hours to measure longitudinal changes in supernatant eATP
concentrations. A 150 µL aliquot was removed from the culture at each time point, drop
plates with dilutions were created, and then the sample was pelleted by centrifugation at 5000
rpm (Eppendorf Centrifuge 5804 R) for 10 minutes. From the cell-free supernatant, 100 µL
was added to an opaque white 96-well plate for eATP assessment. Plates were frozen at 80°C after collection, then thawed for 45 minutes before screening. BacTiter-Glo microbial
cell viability assay, which uses luminescence-based quantification, was employed to
determine the concentration of ATP in the supernatant. A VDMP-ATP standard curve was
created and used to quantify luminescence, then correlated to CFU. A growth curve was run
concurrently with samples from the cultures using the plate reader [Eon Biotek, VT] at
OD600 and 37˚C to determine growth phases.

2.3.4

Proteus mirabilis 296 directional growth assays

Overnight liquid cultures of E. coli IA2 and P. mirabilis 296 were grown in LB aerobically
overnight at 37°C; L. gasseri KC-1 was grown in MRS anaerobically at 37°C overnight.
After growth E. coli IA2 and L. gasseri KC-1 were centrifuged at 5000 rpm (Eppendorf
Centrifuge 5804 R) for 10 minutes, then the supernatant was filter sterilized with a 0.22 µm
sterile syringe filter. To determine what impacts directional growth, L-shaped patterns were
drawn along LB agar aseptically of 30 μL of 10 μM ATP [Sigma, St. Louis, MI], ddH 20, E.
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coli IA2 or L. gasseri KE-1 supernatant. The ATP concentration was determined based on
infective bladder levels of eATP. The hinge of the L allows for the observation of a
directional change in bacterial swarming. After applying the treatment, plates were allowed
to dry at room temperature completely, then 10 µl of P. mirabilis 296 overnight culture was
applied at the start of the pattern (Figure 2-1). Dried plates were then incubated at 37°C
aerobically and photographed every 2-hours with AlphaImager (15/30 second ReflectiveWhite) between 6 and 14 hours of growth to track directional growth.

2.3.5

Statistical analysis

All statistical comparisons were performed using GraphPad Prism 9.1 software. Anaerobic
and aerobic data were statistically compared with a two-way analysis of variance (ANOVA),
complemented with Sidak’s multiple comparisons test. CFU and eATP concentrations were
correlated with a two-tailed Persons test, and a simple linear regression was fit to the data.
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Figure 2-1. Proteus mirabilis 296 directional growth assay. Application of 30 μL of 10 μM
ATP, ddH20, E. coli IA2 or L. gasseri KE-1 supernatant along treatment line followed by
inoculation of P. mirabilis 296 at the base. Growth was monitored over 24 hours. Created
using biorender.com.
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2.4 Results
2.4.1

Bacterial release of ATP during growth

Bacterial release of ATP was quantified after anaerobic growth for 24-hours by luminescence
(Figure 2-1). Secretion of ATP is not species-specific; there were significant differences
between bacterial strains of the same species (two-way ANOVA, P < 0.001, Figure 2-1A-D).
The highest producers were Streptococcus pyogenes NGAS979, S. pyogenes MGAS8232, S.
equisimilis T-148, and S. anginosus T-29. The lowest producers were Enterococcus faecalis
ATCC 33816, Bacillus subtilis 168, and Limosilactobacillus reuteri RC-14. S. pyogenes
NGAS979 released the most ATP (10.675 µM to 14.875 µM during growth); L. reuteri RC14 was the lowest producer, consuming ATP from the MRS media while it grew. Beneficial
LAB produced lower amounts of eATP under 0.2 µM (Figure 2-1A). Pathogenic and
commensal E. coli strains produced a greater range of eATP, up to 0.4 µM (Figure 2-1B).
Streptococcus produced more eATP than all other examined bacteria, up to 14 µM,
significantly higher than all other species (two-way ANOVA, P < 0.001) (Figure 2-1C).
Other pathogens and uropathogens had lower eATP levels (under 0.15 µM) than some
commensal species (Figure 2-1D).
Since cellular respiration may be linked to the bacterial release of ATP, a comparison was
made between aerobic and anaerobic growth (Figure 2-2). Uropathogenic and commensal
bacteria were grown in the same conditions with and without oxygen. There were differences
found for ATP release in anaerobic conditions (two-way ANOVA). The urogenital
environment is anaerobic, so these values represent what might be present during an infection
in the urinary tract. Under anaerobic conditions, uropathogenic E. coli CFT073 had a six-fold
increase in ATP released (two-way ANOVA, P < 0.001), E. coli K-12 has a three-fold
increase (two-way ANOVA, P < 0.001), and commensal E. coli Nissle 1917 had a nine-fold
increase (two-way ANOVA, P = 0.0015). There was no significant difference observed in the
other bacteria.
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Figure 2-2. Bacteria release ATP during growth. Bacterial eATP (µM) in culture
supernatant, normalized to CFU and a media specific ATP standard curve, following 24-hour
anaerobic incubation. (A) LAB, previously all Lactobacillus. (B) E. coli pathogenic and
commensal. (C) Various Streptococcus, S. pyogenes (Groups A, N and C). (D) Other bacteria
of interest. Data are displayed as mean ± SD (n=2-3 biological replicates with 3 technical
replicates (L. reuteri RC-14 n=3 no technical replicates)).

50

Figure 2-3. Anaerobic respiration can affect ATP release in some bacteria. Bacterial
eATP (µM) in culture supernatant, correlated to CFU, following 24-hour aerobic or
anaerobic incubation. Data represent mean ± SD (two-way ANOVA) (n=2-3, anaerobic
values have 3 technical replicates). **p<0.01, ****p<0.0001, all others are not significant.
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2.4.2

Extracellular ATP fluctuations during growth of E. coli IA2 and
L. crispatus ATCC 33820

To determine if eATP levels fluctuate with bacterial growth phase, E. coli IA2 and L.
crispatus ATCC 33820 eATP concentrations were monitored over 24 hours, and the results
were compared to a growth curve and normalized to CFU (Figure 2-3). Anaerobic growth
conditions and VDMP were used to mimic the urogenital environment. E. coli IA2 eATP
levels peaked at the start of log-phase growth, then reduced rapidly during growth and
stationary phase (Figure 2-3A, Top). There was a correlation between E. coli IA2 CFU and
eATP (Pearson correlation, two-tailed, r = -0.1665, r 2 = 0.02773, P = 0.3706); linear
regression is shown with the fitted line, which shows the proportional decrease of eATP with
increased bacterial counts (Figure 2-3A, Bottom). L. crispatus ATCC 33820 eATP levels
increased during log-phase growth, peaking near the end, then reduced rapidly during
stationary phase growth with a slight increase in the last four hours (Figure 2-3B, Top).
There was no correlation between L. crispatus ATCC 33820 CFU and eATP (Pearson
correlation, tow-tailed, r = 0.0581, r2 = 0.003381, P = 0.7560); linear regression shows that as
eATP and bacterial counts tend to increase and decrease together (Figure 2-3B, Bottom).
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Figure 2-4. eATP concentrations fluctuate with anaerobic bacterial growth of E. coli
IA2 and L. crispatus ATCC 33820. (A) E. coli IA2 growth curve and eATP in the culture
supernatant (VDMP), top. Correlation of E. coli IA2 CFU and eATP, with linear regression,
bottom. Data points are mean ± SD of 3 biological replicates. (B) L. crispatus ATCC 33820
growth curve and eATP in the culture supernatant (VDMP), top. Correlation of L. crispatus
ATCC 33820 CFU and eATP, with linear regression, bottom. Data points are mean ± SD of
3 biological replicates (Two-tailed Pearson correlation and simple linear regression).
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2.4.3

Influence of eATP on Proteus mirabilis directional swarming

To determine if eATP can influence the directional swarming abilities of uropathogenic P.
mirabilis 296 bacterial supernatants with high eATP concentrations and a 10 µM ATP
solution were added in an “L” pattern to agar plates; then swarming directionality was
qualitatively assessed (Figure 2-4). Cell-free supernatant from E. coli IA2 (~0.05 µM ATP)
and L. gasseri KC-1 (~0.025 µM ATP) were applied to assess if swarming could follow
bacterial ATP released during growth of other urogenital bacteria. Non-directional swarming
(expansion from the point of inoculation in a ring fashion) is seen with the ddH 2O control
and the L. gasseri KC-1 supernatant. With both the ATP and E. coli IA2 supernatant
treatments, there is a similar directional influence observed. In early-phase growth
(consolidation), there is an observable direction change at the crux of the “L”, and in latephase growth (swarming), the rings stretch along the treatment line. Comparison of the two
groups shows that higher eATP levels can influence the swarming pattern causing a
directional shift.
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6 hr

8 hr

10 hr

12 hr

14 hr

ddH2O

L. gasseri KC-1
supernatant

10 µM ATP

E. coli IA2
supernatant

Figure 2-5. High levels of eATP influence Proteus mirabilis 296 swarming patterns. Time
series photos of P. mirabilis 296 swarming influenced by eATP (10 µM) and bacterial
supernatant. Each treatment was inoculated along the sharpie line, then P. mirabilis 296 was
added at the “X”. Plates were incubated anaerobically at 37°C and photographed with
AlphaImager (15/30 second Reflective-White) every 2 hours between 6- and 14-hours postinoculation (n=3, only one plate pictured which is representative of the general observed
trends).
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2.5 Discussion
This study investigated the bacterial release of ATP during growth and the impact eATP has
on uropathogenic P. mirabilis 296 swarming. A range of pathogenic and commensal bacteria
(Gram-positive and Gram-negative) were selected, and their ATP release was quantified after
24 hours of growth. There was a significant variance in eATP concentrations between
pathogenic and commensal bacteria. Previously, lactobacilli were shown to produce less
eATP (~0.025 µM) than pathogenic bacteria (0.1-1 µM) 3,10,26, and this study’s findings
further support that claim. In addition, strains of the same species had significantly different
eATP levels, suggesting that the release of eATP is species and strain specific.
Commensal lactic acid bacteria had a lower range of ATP release than the other observed
bacteria, ranging from -0.014 µM by L. reuteri RC-14 to 0.077 µM by Lacticaseibacillus
rhamnosus GG. The lower eATP concentrations observed in Lacticaseibacillus
Lactiplantibacillus and Limosilactobaillus spp., align with previously observed low eATP
levels, compared explicitly to uropathogenic species10. The eATP concentration for L.
crispatus ATCC 33820 was 0.039 µM after 24 hours of growth which is higher than
previously observed10 but correlates with observed increases in late phase growth.
Specifically, eATP levels decreased in early stationary phase then increased as growth
approached 24 hours, suggesting a link to nutrients availability. The probiotic L. reuteri RC1447–49 was the only strain to reduce eATP from the medium (MRS). All other bacteria
released ATP and potentially consumed it during growth. Studies have shown that L. reuteri
RC-14 can confer health benefit to the vagina and these findings raise the possibility that its
consumption of eATP could be a factor in conveying the host benefit in the urogenital
system47–49.
There was significant variation in E. coli ATP release between strains and generally
significantly higher concentrations of ATP compared to commensal species. Probiotic E. coli
Nissle 1917 had significantly higher ATP release (0.12 µM) compared to several commensal
species, which might be related to a generally higher ATP release in E. coli. The most
significant producer was E. coli CFT073, a known uropathogen; the lowest producer was E.
coli DSM 103539, isolated from a case of asymptomatic bacteriuria 50. The lack of symptoms
in an infection caused by E. coli DSM 103539 could be related to its lower ATP release;
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potentially, it is less pathogenic due to lower eATP. Both P. mirabilis and E. faecalis are
associated with recurrent, catheter, and asymptomatic UTIs 51–53. The increased symptomatic
presentation associated with higher ATP suggests a correlation; infections with decreased
symptoms have eATP concentrations comparable to commensal strains. Reduced ATP could
play a role in the asymptomatic presentation of infections. With reduced bacterial eATP,
there could be a reduction in purinergic host signaling, leading to less bladder epithelium
interaction, host immune interaction, pain, and reduced contractions 15,19. E. coli IA2 was
isolated from a patient with symptomatic UTI and has lower levels of eATP measured at 24
hours. During growth, E. coli IA2 released 1.9 µM before log phase, which is sufficient to
cause contractions through purinergic signaling10.
The release of ATP has been linked to biofilm formation 33; however, this has not been
studied in the bladder environment. Increased biofilm formation is seen with ATP
supplementation in E. coli K-1233, which released 0.31 µM of ATP, relatively higher than
other E. coli. A common cause of recurrent and catheter-associated UTI, P. mirabilis53,54, can
swarm using the same genetic pathways as biofilm formation 55 and could be influenced by
ATP. Biofilm formation plays a crucial role in P. mirabilis virulence32,35 and could reduce
the need for environmental modulation by eATP, as P. mirabilis 296 released 0.07 µM of
ATP. Release of ATP by other uropathogens, the host, or both could promote P. mirabilis48
to seek the site where a primary infection is occurring, which could lead to co-infection with
other uropathogens to worsen the condition.
As part of our wider evaluation of ATP releasing organisms, we tested other less typically
common urogenital tract isolates and other human disease-associated bacteria, including S.
pyogenes. One of the most common sources of invasive infection in humans, S. pyogenes
(group A, GAS), causes 700 million infections per year, some with serious sequelae 56.
Interestingly, the Streptococcus genus includes many species that colonize human mucosal
membranes (>100 species), and they are primarily opportunistic pathogens causing infections
in response to weak immune systems56. Human-colonizing and other Streptococcus were
screened, both known pathogenic and infrequent opportunistic infectors. These had the most
significant variation of all screened genera, with a range of 0.03 µM by S. uberis ATCC
27958 to 13 µM by S. pyogenes NGAS979 (a 433-fold difference). The S. pyogenes
NGAS979 was one of the strains responsible for the 2015 Canada-wide invasive infection
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outbreak57 and released significantly more ATP than all other species screened. These
finding supports the idea that eATP plays a role in virulence, and higher levels could
contribute to modulating the site of infection on the skin as they do in the bladder. Perhaps,
in a host with a weakened immune system, ATP release can aid in the switch from colonizer
to pathogen. On the skin, ATP has been found to play a similar role in neurotransmission
through purinergic receptors to trigger pain 15,58.
Previously, bacterial ATP release has been linked to cellular respiration efficiency and
nutrients availability6,59. Comparing aerobic and anaerobic growth conditions, we observed a
significant increase in ATP release in three species and generally higher ATP levels in
anaerobic growth. Mempin et al.3 observed reduced eATP in cytochrome bd oxidase E. coli
K-12 knockouts grown aerobically. We observed a significantly higher eATP level by E. coli
K-12 with anaerobic growth, and though both conditions lead to a reduction in cellular
respiration, they may not be comparable. A possible reason for the discrepancy between our
results and theirs is using a knockout versus modifying the growth environment. As the ATP
release mechanism is unknown, it might not be linked to cytochrome bd oxidase, and the E.
coli K-12 knockout released less ATP due to loss of cellular respiration. Although cellular
respiration reduces ATP in anaerobic conditions, the pathway is not impaired, and a
bacterium could still release high concentrations of ATP. Many of the bacteria we screened
are uropathogenic species and infect in an anaerobic environment. Similar growth conditions
to the infective environment resulting in higher eATP could further support release being
linked to virulence.
In the E. coli IA2 and L. crispatus ATCC 33820 cultures, the growth phase was shown to
regulate eATP levels. The most significant extracellular concentrations of ATP in both
strains were observed during log-phase growth followed by a decrease in the stationary
phase; E. coli IA2 eATP peaked at 7 hours around the start of log-phase growth reaching 1.9
µM, followed by rapid depletion during log-phase growth, which continued in the stationary
phase until the eATP was almost entirely depleted. Mempin et al.3 observed peak eATP
around late log phase, which was about 14 nM; similarly, we have a secondary peak of 14
nM in later log phase. The differences in eATP peak concentrations here are potentially due
to fewer time points observed by Mempin et al.3. We sampled every 30 minutes (0-6 hours)
and every hour after, whereas they sampled at 0, 3, 6, 9, and 24 hours; the reduced time
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points may have resulted in a missed peak concentration. The L. crispatus ATCC 33820
eATP peaked at 8 hours near the end of log-phase growth and depleted rapidly for 5 hours
into stationary phase before increasing slightly. The release and depletion of ATP during
growth suggests a relation to the growth phase that is bacteria species-specific and has been
previously observed in Lactobacillus and E. coli3,10.
High concentrations of ATP and E. coli IA2 supernatant influenced uropathogenic P.
mirabilis 296 directional swarming patterns. Classic P. mirabilis growth on agar can be
broken into two phases, consolidating (the thicker white ring) and swarming (the clear
ring)60. The consolidation phase initiates growth and is a resting phase during which there is
an upregulation of nutrient uptake systems, central metabolism, and respiration 60. This
swarming motility could initiate a catheter-associated UTI by allowing migration from the
periurethral region to the bladder37. Due to the similarity between biofilm formation and
swarming33,55, we investigated if eATP could have a similar effect on swarming as it does on
biofilm formation. Using both ATP and bacterial supernatant, the same impact on P.
mirabilis 296 growth was found, indicating that E. coli IA2 eATP can influence the growth
of another uropathogenic organism. On the contrary, L. gasseri KC-1 supernatant had no
effect on swarming direction, suggesting the lower levels of ATP in commensal species may
not influence their growth. During the consolidation phase, there was growth along the line
which diverges from the standard ring to preferentially travel along the supplemented path. In
the bladder, when there are increased ATP concentrations, infected or not, P. mirabilis 296
could respond similarly with directed swarming up a catheter, urethra or inside the bladder,
accelerating infection onset.
We detected eATP from a wide range of bacterial species, supporting the idea that there may
be an un-deciphered bacterial-environmental-ATP link. The release mechanism is not yet
identified, nor is the impact bacterial ATP has on the host fully understood. The observation
of higher ATP levels is generally associated with known pathogenic species, which supports
the connection to virulence and the establishment of infection. The bacterial release of ATP
may play a role as a nutrient molecule or signaling molecule to the bacterial community. The
reduction and release of ATP in a bacterial growth-phase-dependent manner could be
bacteria using the environment to store excess energy to use later in growth when nutrient
levels are decreased. Once released, ATP could similarly provide nutrients for other species
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as well as communicate proximity and directionality. The role of eATP release in bacteria
needs further characterization; however, this study furthers the idea that it does play a role in
bacterial growth, communication and the potential impact on the environment.

2.5.1

Conclusion

The release of ATP was demonstrated during the growth of pathogenic and commensal
Gram-negative and Gram-positive bacteria. During growth, eATP levels fluctuate, increasing
during log-phase then depleting in stationary phase, suggesting release is growth-phase
dependent. Bacterial and supplemented ATP can regulate and change the growth patterns of
swarming P. mirabilis 296, a uropathogenic species that infects an ATP-saturated
environment. The fluctuations in eATP and variation between species suggest that bacterial
eATP has hitherto undiscovered functions related to the releasing bacteria, the bacterial
community and the host environment.
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Chapter 3

3

The potential role of lactobacilli to modulate extracellular
ATP

This chapter focused on the role lactobacilli potentially play in mitigating extracellular ATP
(eATP) in the urogenital environment. It also examined if prebiotic substances can enhance
lactobacilli and, in turn, reduce ATP in vitro, potentially leading to a novel treatment path for
urinary tract infection (UTI), overactive bladder (OAB) and urgency urinary incontinence
(UUI).

3.1 Abstract
Urogenital microbiota disruption and divergence from lactobacilli dominance is often
associated with UTI, OAB and UUI. Increased levels of eATP observed in these conditions
are unaddressed by current treatments. Prebiotic substances have been shown to bolster
indigenous lactobacilli in the intestine and vagina. We hypothesized that certain prebiotic
compounds could stimulate growth of urinary lactobacilli and reduce urinary ATP levels to
those associated with good health. Lactobacillus crispatus ATCC 33820, Lactobacillus
gasseri KC-1 and uropathogenic Escherichia coli IA2 were tested for their ability to utilize
ten prebiotic candidates. Of those, D-mannose, raffinose and sodium acetate were found to
enhance lactobacilli growth but not that of E. coli IA2. In addition, when cultured with
urothelial cells, exposure to D-mannose and raffinose enhanced lactobacilli growth in a coculture with E. coli IA2 and increase eATP reduction from culture. The interaction between
eATP and bacteriocin regulation was also investigated in this chapter, as it was postulated
that it could be a mechanism to acquire intracellular ATP from other bacteria. In deferred
bacteriocin assays, the inhibitory activity decreased in the presence of eATP, indicating that
bacteriocin production could be related to ATP availability. These in vitro culture-based
studies demonstrated that lactobacilli could modulate eATP.
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3.2 Introduction
A healthy female urogenital tract has a microbiota dominated by lactobacilli 1,2. These
commensal microbes modulate the environment by producing lactic acid, bacteriocin-likemolecules, hydrogen peroxide, and biosurfactants, limiting pathogenic adherence 3,4. In
urogenital diseases, including UTI and OAB, there is often a decline in Lactobacillus
species5,6. Antibiotics and lifestyle modification are often used successfully to treat
complicated and uncomplicated UTIs7. Lifestyle modifications such as pelvic floor training,
timed fluid consumption and micturition, and bladder training are the primary treatments for
OAB8. There are also several OAB drug treatments which relax the bladder to relieve
urgency9. Despite the occurrence and awareness of OAB, most treatments are unsatisfactory
according to patients8–10.
Urogenital microbiota changes, sometimes broadly defined as dysbiosis, are commonly
found in UTI and OAB patients and are unaddressed by interventions. It is known that
antibiotic use can disrupt the urogenital microbiota for months following treatment of an
infection11. However, studies have shown that a lactobacilli-dominated microbiota can be
recovered with the consumption of probiotic Limosilactobacillus reuteri RC-14 and
Lacticaseibacillus rhamnosus GR-111,12. Though not a primary therapy for UTI or OAB,
probiotics could help manage these conditions by restoring the microbiota 13–16.
Another potential treatment option still in its relative infancy for OAB and UTI is the use of
prebiotics, defined as, "a substrate that is selectively utilized by host microorganisms
conferring a health benefit"17. Prebiotics mainly used in humans are typically complex
carbohydrates including fructans (fructooligosaccharides (FOS) and inulin), galactans
(galactooligosaccharides (GOS)), and human milk oligosaccharides (HMO). These molecules
are thought to promote bifidobacteria and lactobacilli but not pathogenic microorganisms,
such as E. coli18–20. There could also be other compounds with prebiotic potential, including
sugar alcohols (maltitol, lactitol, and xylitol)21, lactulose (disaccharide)22, raffinose
(trisaccharide)23, and short-chain fatty acids (acetate, butyrate)24. More complex substrates,
such as lyophilized skim milk, have also been used as a prebiotic to supplement L.
rhamnosus GR-1 in capsules to address lactobacilli loss in women with recurrent UTIs and
urogenital infections25,26. In human and in vitro studies, lactobacilli growth is enhanced by
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GOS27,28, FOS28,29, and HMO30–32. Collins et al. 33 identified lactulose as a vaginal prebiotic
candidate that can selectively enhance the growth of lactobacilli while antagonizing vaginal
pathogens. D-mannose is also a potential urogenital prebiotic because it can effectively
reduce the risk of recurrent UTIs and limit E. coli adhesion to bladder cells enabling better
clearance34,35. Prebiotics could be used to increase native lactobacilli presence or combined
with probiotics to disrupt an infectious microbiota by shifting it towards one associated with
health. The increased commensal presence could reduce the uropathogenic microbial load
and impact.
Promoting a urogenital microbiota predominant in Lactobacillus could, in turn, reduce eATP
and its potentially adverse effects on the bladder. In the bladder, one function of ATP is to
signal bladder fullness through purinergic receptors in the epithelium 36. In patients with UUI,
lower urine volumes have ATP concentrations equivalent to a full bladder in a healthy
patient, thereby causing the urgency feeling37,38. The ATP released by uropathogenic E. coli
IA2 impacts host Ca2+ influx and smooth muscle concentrations; however, L. crispatus
ATCC 33820 and L. gasseri KC-1 can reduce this effect39,40. While some lactobacilli have
already been shown to positively impact the bladder environment, the relationship between
ATP and Lactobacillus is still not well understood.
In considering how lactobacilli might influence other organisms and host responses, it is
worth examining bacteriocins. These are proteinaceous antimicrobial agents produced by
bacteria, including lactobacilli. Some bacteriocins are cytolytic in nature against their
bacterial targets and cause release of ATP into the environment 41. Therefore, production of
bacteriocins may be a means by which bacteria further attain ATP from competitive
microbes. Several lactobacilli express bacteriocins or bacteriocin-like molecules, including L.
crispatus ATCC 33820, which has been shown to have a cytotoxic effect on E. coli in
vitro42,43. A vaginal isolate from a healthy woman, Lacticaseibacillus rhamnosus 160
produces bacteriocin lactocin 160, which can inhibit vaginal pathogens, including
Gardnerella vaginalis44. Vaginal isolates L. salivarius subsp. salivarius CRL 1328 and L.
acidophilus XH1 and probiotic strain L. acidophilus KS400 produce a bacteriocin that is
active against urogenital pathogens45–47. In preliminary studies, we have shown that in the
presence of excess eATP, bacteriocin activity is decreased, suggesting these substances may
play a role in ATP release. We hypothesize bacteriocin expression could increase to facilitate
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the acquisition of ATP from other bacteria when nutritional availability is diminished and
vice versa when nutrition is restored. Thus, ATP release could be adding to uropathogen
virulence by decreasing bacteriocin production and limiting environmental competition.
In this study, the overall goal was to investigate the ability of Lactobacillus spp. to limit the
effects of eATP release by uropathogenic species. Specifically this study aimed to identify
potential prebiotics for use in a bladder environment to enhance lactobacilli reduction of
eATP. Additionally, the relationship between ATP and bacteriocin production was
investigated using standard producers and an indicator strain 48.

3.3 Methods and Materials
3.3.1 Strains and growth conditions
Escherichia coli IA2 was maintained on lysogeny broth agar [LB; Difco, MD] and grown in
LB broth aerobically at 37˚C. L. gasseri KC-1 and L. crispatus ATCC 33820 were
maintained on de Man, Rogosa and Sharpe agar [MRS, Difco, MD] and grown in MRS broth
in an anaerobic jar at 37˚C. All Streptococcus were maintained on brain heart infusion agar
with 0.005% added yeast extract [BHYE, BD Bacto] or Todd-Hewitt agar [TH, SigmaAldrich, St. Louis, MO] grown in those broths aerobically at 37˚C and 5% CO 2. The standard
bacteriocin indicator strain Micrococcus luteus T-1848 was maintained and grown in BHYE
and TH at 37˚C and 5% CO2.

3.3.2 Prebiotic impact on bacterial growth
Ten different candidate substances with potential prebiotic properties were examined to
assess their impact on commensal and uropathogenic bacterial growth. Selected prebiotic
candidates were; lactulose [Alfa Aesar], D-(+)-mannose [Sigma-Aldrich, MO], 2’-Ofucosyllactose [Glycom, DK], lacto-n-neotraose [Glycom, DK], lacto-n-tetraose [Glycom],
6’-O-sialyllactose [Glycom], D-(+)-raffinose [Sigma-Aldrich], sodium acetate [Fisher
Scientific, MA], ATP [Sigma-Aldrich] and arabinogalactan [Sigma-Aldrich]. Growth curves
were used to investigate the impact on uropathogenic E. coli IA2, commensal L. crispatus
ATCC 33820 and L. gasseri KC-1. Several minimal media were used to elucidate prebiotic
effect and mimic the urogenital environment: minimal salt media (MSM) without yeast
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extract49, dextrose free vaginally defined medium with peptone (dfVDMP) 50, carbohydratefree vaginally defined medium with peptone (cfVDMP)50,carbohydrate-free MRS (cfMRS),
artificial urine51 with and without tryptic soy broth [TSB, Difco], and 10X diluted MRS and
LB. Prebiotics were supplemented into media at concentrations of 0.5%, 1%, 5%, and 10%
(wt/vol) then media were sterilized by 0.22 µM filtration. Bacteria were grown overnight and
then diluted (10-2) in a minimal medium for prebiotic screening. Growth curves at 37˚C were
created using a plate reader for 20-24 hours with reads at optical density 600 nm (OD600)
every 30 minutes after a 15-second shake [Eon Biotek, VT].

3.3.3 ATP quantification
A luminescent assay kit (BacTiter-Glo Microbial Cell Viability Assay [Promega, WI,
G8230]) was used to quantify eATP released by the bacteria and urothelial cells in cell-free
supernatant. The manufacture’s protocol was followed for sample and reagent preparation. A
standard ATP curve was prepared according to the manufacturer’s protocol in the media used
for each screening. Luminescence was measured with a microplate reader (Synergy™ H4
Hybrid Multi-Mode [BioTek, USA]) from which ATP could be quantified.

3.3.4 ATP depletion assay
Reduction of ATP from media with and without a prebiotic was assessed with L. crispatus
ATCC 33820 and L. gasseri KC-1 in dfVDMP. Three treatments were tested: medium only,
0.1 mM ATP supplemented medium and 0.1 mM ATP with 0.5% (wt/vol) prebiotic
supplemented medium. For each treatment and time point, 1.5 mL of medium was added to a
microfuge tube (n=3), then 10 µL of bacteria from an overnight culture was added, and tubes
were incubated at 37˚C. At 0, 3.5, 4.5, 5.5, 6.5 and 24 hours, three tubes were removed to
enumerate CFU and ATP. Drop plates were created from dilutions on MRS agar and grown
overnight anaerobically. The remaining sample was pelleted by centrifugation at 14,000 × g
for 10 minutes, then 100 µL cell-free supernatant was added to an opaque white 96-well
plate. Biological replicates were measured in technical duplicate, and an ATP standard curve
with dfVDMP was added to the plate. All plates were frozen at -80˚C and thawed for 45
minutes before screening with BacTiter-Glo Microbial Cell Viability Assay. The
luminescence-based results were then correlated to the standard curve and CFU.
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3.3.5 Bacteriocin deferred growth assay
Bacteriocin producers and an indicator strain (M. luteus T-18) were grown overnight at 37°C
and under 5% CO2 in TH or BHYE broth. From the overnight culture, 100 µL of each
bacteriocin-producing stain (Supplementary, Table 3-2) was inoculated down an agar plate
(TH or BHYE) tilted at 90° to create a single line of growth then air dried (n=3-4). The
producing strain was exposed to 1 µg/10 µL of ATP in sterile water on a disk during growth
or 10 µL of sterilized ddH2O. Time trials were completed to determine the ideal growth time
for each producer for observation of a zone of inhibition (ZOI). Plates were then incubated at
37°C and 5% CO2 for 12-24 hours, depending on the bacteriocin under investigation. After
incubation, the producing strain was cleaned off the plate using a sterile cotton swab dipped
in ddH2O and disks were removed. The plate was placed over a filter paper disk covered in
chloroform for 45 minutes to surface sterilize, then dried in a fume hood for an additional 20
minutes. A lawn of indicator strain M. luteus T-18 was added to the plate and incubated for
24-48 hours at 37°C, under 5% CO2. Plates were imaged using white light at 24, 36 and 48
hours with an AlphaImager. The ZOI and growth into the ZOI were qualified using ImageJ,
with threshold quantification used to quantify growth into the ZOI. (Figure 3-1).
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Figure 3-1. Bacteriocin deferred growth assay. Producing strains were grown overnight,
then 100 µL was dripped down the plate to create a growth line. Next, a blank disk with ATP
at 1 mg/ 10 µL or ddH2O was added beside the producer line. After 12-24 hours of growth,
the producer strain was cleaned from the plate re-sterilized with chloroform. After resterilization, a lawn of M. luteus T-18 was added, and the plates were re-incubated for 24-48
hours. Finally, plates were imaged, and ImageJ was used to quantify growth into ZOI.
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3.3.6 RNA extraction and reverse transcription
Streptococcus uberis 42 was grown overnight in BHYE broth at 37°C and 5% CO 2. From
culture, 100 µL was dripped down a BHYE agar plate, as in the deferred growth assay. An
ATP disk with 1 µg/10 µL or ddH2O was placed beside the culture line before incubation
(n=6). Plates were incubated for 18 hours at 37°C and 5% CO 2 to ensure bacteriocins and
other virulence factors were produced. RNA extraction was completed using TRIzol®
Reagent with the PureLink® RNA Mini Kit, the manufacturer’s protocol was followed for
sample and reagent preparation with the following modifications. First, sterile loops were
used to transfer a 1 cm2 area of bacteria adjacent to the disk to 500 μL of TRIzol reagent
[Ambion, TX] and 0.1 mm zirconia beads. Samples were then bead beaten twice for 30
seconds at 4,800 rpm with a BeadBug™ 6 microtube homogenizer [Sigma-Aldrich, St.
Louis, MO]. Next, 100 μL of chloroform was added, and two chloroform washes were done
to reduce phenol contamination; the second was equal volume to the aqueous upper layer.
Next, the On-column PureLink® DNase treatment was used to ensure the RNA was DNAfree. RNA was eluted in 30 μL of 56°C nuclease-free H2O, then evaluated using a DeNovix
DS-11 Spectrophotometer and determined to have A260/280 and A260/230 ratios between
1.7–2.2 and 1.8–2.4 respectively. High-Capacity cDNA Reverse Transcription Kit was used
to make cDNA following the manufacturer's instructions [Applied Biosystems, CA].

3.3.7 Quantitative PCR analysis
PowerTrack SYBR Green Master Mix [Applied Biosystems, CA] was used for quantitative
PCR (qPCR). Primers from Lasagno et al.52 were used to identify ubericin A (ubaA), ubericin
A immunity protein (ubaI), uberolysin A (ublA), and Lantibiotic nisin-U (nsuA and nsuB)
(Supplementary, Table 3-3). For gene expression analysis, gyrB was used as the
endogenous reference gene, an identified stably expressed reference gene 53. The total
reaction was 10 μL, including 4.5 μL of cDNA (diluted 6× in nuclease-free H 2O), 5 μL of
SYBR (2×), and 0.5 μL of mixed forward and reverse primers (500 nM final concentration).
QuantStudio 5 Real-Time PCR System [Thermo Fisher Scientific] was used to run qPCR;
reaction conditions were 50℃ for 2 minutes, then 95°C for 10 minutes, followed by 40
cycles of 95°C for 15 seconds and 60°C for 1 minute. Final analysis was completed with
QuantStudio 5 Real-Time PCR System [Thermo Fisher Scientific] and associated
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QuantStudio Design and Analysis Software v1.5.1 [Thermo Fisher Scientific]. Fold change
was used to calculate gene expression (2−ΔΔCt), and statistics were performed on the –ΔΔCt
values54.

3.3.8 Cell and bacteria co-culture experiments
Bladder epithelial cells [5637, ATCC HTB-9] passage number 4-7 were maintained in RPMI
1640 [Roswell-Park Memorial Institute media 1640, Thermo Fisher Scientific, MA]
supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine at 37°C and 5%
CO. The medium was refreshed as needed once the cells reached confluency (90-100%,
about every 48 hours). Next, the spent medium was removed, and cells were washed with
phosphate-buffered saline (PBS), then trypsinized by 0.25% Trypsin-EDTA [Gibco, MA].
Cell co-culture experiments were run after cells had reached confluency. All cells were used
for up to a maximum of four passages (P8-11) before being discarded.
Cell co-culture experiments were undertaken with bladder epithelial cells (5637) and bacteria
to compare eATP levels with and without prebiotics. Uroepithelial cells were seeded (~0.3
million/well) into 24-well plates and grown to 90% confluency in 2 mL RPMI 1640. Anontoxic dose of 0.5% (wt/vol) prebiotic was added to the cell culture medium without FBS.
Prebiotics were selected based on efficacy from growth curves earlier in the study, lactulose,
D-(+)-mannose, and D-(+)-raffinose. In addition, a co-culture of E. coli IA2 and L. crispatus
ATCC 33820 or L. gasseri KC-1 was added at a multiplicity of infection of fifty. The plate
was incubated at 37°C and 5% CO2 for six to eight hours. After growth was complete, cell
viability (using Invitrogen Countess Automated Cell Counter [Thermo Fisher Scientific]) and
morphology were determined.
During growth, samples were collected every 30 minutes; 150 µL was removed from each
well aseptically to create CFU drop plates and screen eATP. Drop plates were done on LB
and MRS agar grown overnight aerobically or in an anaerobic jar, respectably at 37°C. The
remaining sample was pelleted by centrifugation at 14,000 × g for 10 minutes, then 100 µL
of cell-free supernatant was added to an opaque white 96-well plate for ATP screening.
Plates were frozen at -80°C after collection, then thawed for 45 minutes before screening.
BacTiter-Glo Microbial Cell Viability Assay was used to determine the concentration of ATP
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in the supernatant. An ATP standard curve was created in RMPI-1640 and used to normalize
luminescence.

3.3.9 Statistical analysis
All statistical comparisons were performed using GraphPad Prism 9.1.1 software. Non-linear
regression (K) and area under the curve (AUC) were compared using ordinary one-way
analysis of variance (ANOVA). Data were tested for normality using D’Agostino and
Pearson test. A two-way ANOVA was used to statistically compare experiments with two
factors, complemented with Tukey's multiple comparisons test. Normally distributed data
were compared with an unpaired, two-tailed t-test, with Welch's correction.

3.4 Results
3.4.1 Prebiotic impact on Lactobacillus and E. coli growth
Bacterial growth curves were compared to identify ideal prebiotics. The media used
mimicked the urogenital environment. Growth curves were initially compared based on
exponential growth rate then by the area under the curve as it was a more standard value. Of
the ten tested potential prebiotic substances, only lactulose, D-mannose, raffinose, sodium
acetate, and 6’-O-sialyllactose impacted bacterial growth (Table 3-1).
An initial screening found L. crispatus ATCC 33820 growth was enhanced by lactulose
(1%), D-mannose (5%) and LNT (1%) based on K and Y-max (Supplementary Table 3-2,
Supplementary Figure 3-7). In minimal TSB-free artificial urine L. crispatus ATCC 33820
growth was enhanced by lactulose (5%) (K, one-way ANOVA, p=0.0319), and D-mannose
(1% and 5%) (K, one-way ANOVA, p=0.0195, p=0.0076) (Supplementary Table 3-2,
Supplementary Figure 3-8). In artificial urine with 0.5% prebiotic, L. crispatus ATCC
33820 growth was significantly enhanced by lactulose (K, one-way ANOVA, p<0.0001), Dmannose (K, one-way ANOVA, p<0.0001), and raffinose (K, one-way ANOVA, p<0.0001)
(Supplementary Table 3-2, Supplementary Figure 3-9). A prebiotic concentration of 0.5%
had no impact on L. crispatus ATCC 33820 in VDMP (Supplementary Table 3-2,
Supplementary Figure 3-9). In minimal medium cfVDMP, cfMRS, and MSM
supplemented with 1% prebiotics, L. crispatus ATCC 33820 growth was significantly
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enhanced by D-mannose (AUC, one-way ANOVA, p<0.0001) (Supplementary Table 3-2,
Supplementary Figure 3-10). Lactulose (1%) significantly inhibited growth in L. crispatus
ATCC 33820 in cfVDMP (AUC, one-way ANOVA, p<0.0001); growth was significantly
enhanced by lactulose (1%) in cfMRS (AUC, one-way ANOVA, p<0.0001)
(Supplementary Table 3-2, Supplementary Figure 3-10). Raffinose (1%) significantly
inhibited the growth of L. crispatus ATCC 33820 in cfVDMP (AUC, one-way ANOVA,
p<0.0001) (Supplementary Table 3-2, Supplementary Figure 3-10). There was significant
reduction in L. crispatus ATCC 33820 growth with sodium acetate (1%, 2.5% and 3%) in
10× diluted MRS (AUC, one-way ANOVA, p<0.0001) and VDMP (AUC, one-way
ANOVA, p=0.0002, p=0.0001, p=0.0002) (Supplementary Table 3-2, Supplementary
Figure 3-12, 13).
In minimal TSB-free artificial urine E. coli IA2 growth was significantly enhanced by Dmannose (1% and 5%) (K, one-way ANOVA, p=0.0495, p<0.0001), and raffinose (5%) (K,
one-way ANOVA, p=0.0173) (Supplementary Table 3-2, Supplementary Figure 3-8). In
artificial urine with 0.5% prebiotic, E. coli IA2 growth was significantly enhanced by
raffinose (K, one-way ANOVA, p=0.0352) (Supplementary Table 3-2, Supplementary
Figure 3-9). In VDMP with 0.5% prebiotic concentration, there was no impact on E. coli
IA2 growth (Supplementary Table 3-2, Supplementary Figure 3-9). In minimal media
cfVDMP, cfMRS, and MSM supplemented with 1% D-mannose, E. coli IA2 growth was
significantly enhanced (AUC, one-way ANOVA, p=0.0091, p<0.0001, p<0.0001)
(Supplementary Table 3-2, Supplementary Figure 3-10). Lactulose (1%) significantly
inhibited growth of E. coli IA2 in cfVDMP (AUC, one-way ANOVA, p=0.0001)
(Supplementary Table 3-2, Supplementary Figure 3-10). Raffinose (1%) significantly
inhibited the growth of prebiotic E. coli IA2 in cfVDMP (AUC, one-way ANOVA,
p<0.0001) and significantly enhanced growth in cfMRS (AUC, one-way ANOVA, p=0.0014)
and MSM (AUC, one-way ANOVA, p=0.0013) (Supplementary Table 3-2,
Supplementary Figure 3-10). E. coli IA2 growth was significantly reduced by sodium
acetate (2.5% and 3%) in 10× diluted LB (AUC, one-way ANOVA, p=0.0426, p=0.046);
there was no significant impact in VDMP (Supplementary Table 3-2, Supplementary
Figure 3-12, 13).
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Raffinose (0.5% and 1%) significantly enhanced L. gasseri KC-1 growth (AUC, one-way
ANOVA, p<0.0001) in VDMP (Supplementary Table 3-2, Supplementary Figure 3-11).
In 10× diluted MRS, lactulose (1%), D-mannose (0.5% and 1%), and raffinose (1%)
significantly reduced L. gasseri KC-1 growth (AUC, one-way ANOVA, p<0.0001,
p<0.0001, p=0.0280, p<0.0001) (Supplementary Table 3-2, Supplementary Figure 3-11).
Prebiotic supplementation had no significant effect on L. gasseri KC-1 growth in artificial
urine (Supplementary Table 3-2, Supplementary Figure 3-11). Growth of L. gasseri KC-1
was significantly enhanced by sodium acetate (1%, 2.5% and 3%) in 10× diluted MRS
(AUC, one-way ANOVA, p<0.0001) and VDMP (AUC, one-way ANOVA, p<0.0001)
(Supplementary Table 3-2, Supplementary Figure 3-12, 13).
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Table 3-1. Average fold change in bacterial growth between control and prebiotic
supplementation
Prebiotic substance
L. crispatus ATCC 33820
E. coli IA2
L. gasseri KC-1
(wt/vol)
Lactulose (0.5%)
++
+
Lactulose (1%)
+
+++
Lactulose (5%)
NA
--D-mannose (0.5%)
++++
-D-mannose (1%)
+++++
+++++
D-mannose (5%)
NA
+
+++
Raffinose (0.5%)
+++
++++
Raffinose (1%)
+++++
-Raffinose (5%)
NA
+
--Acetate (3%)
---+
Acetate (2%)
---++
Acetate (1%)
--+++++
Arabinogalactan (5%)
NA
+
+
6’-O-sialyllactose (5%)
NA
+
LNT (5%)
NA
LNnT (5%)
NA
2-O-Fucosyllactose (5%)
NA
Fold change average: 1 and up + + + + +; 0.76 to 1 + + + +; 0.51 to 0.75 + + +; 0.26 to 0.5 +
+; 0.001 to 0.25 +; -0.001 to -0.25 -; -0.26 to -0.5 - -; -0.51 to -0.75 - - -; -0.76 to -1 - - - -
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3.4.2 Prebiotic impact on supplemented ATP uptake by L. crispatus
ATCC 33820 and L. gasseri KC-1
To assess the prebiotic impact on lactobacilli uptake of ATP, L. crispatus ATCC 33820 and
L. gasseri KC-1 were grown with 1µM ATP in dfVDMP with and without prebiotic at 0.5%
(D-mannose and raffinose, respectively). The eATP concentrations were monitored over 24
hours, normalized to CFU/ mL, and a reduction rate was calculated (ATP µM/hr) (Figure 32). Anaerobic conditions and dfVDMP were used to mimic the urogenital environment.
Initially, L. crispatus ATCC 33820 ATP-D-mannose had significantly higher eATP
concentrations than ATP-alone (one-way ANOVA, p=0.0006); however, by 3.5 hours, they
were not significantly different (Figure 3-2A, Top). The rate of ATP reduction with and
without D-mannose was similar, only significantly different at two time points (one-way
ANOVA, p=0.001, p=0.0176) (Figure 3-2A, Bottom). The addition of raffinose resulted in
significantly higher eATP concentrations than ATP-alone for the first 6.5 hours in L. gasseri
KC-1 (one-way ANOVA, p=0.0051, p<0.0001) (Figure 3-2B, Top). The rate of ATP
reduction with and without raffinose was similar, only significantly different at time point 6.5
(one-way ANOVA, p=0.0002) (Figure 3-2B, Bottom). Both, L. crispatus ATCC 33820 and
L. gasseri KC-1 entirely reduced the supplemented ATP from media after growth (Figure 32).
Supplementation with ATP significantly impacted growth by 24 hours, L. crispatus ATCC
33820 and L. gasseri KC-1 had significantly higher CFU/ mL compared to media alone (twotailed t-test, Tukey's, p<0.0001) (Supplementary Figure 3-14). Prebiotic and ATP
supplemented, L. crispatus ATCC 33820, and L. gasseri KC-1 had significantly higher CFU
compared to media alone by 24 hours (two-tailed t-test, Tukey's, p<0.0001, p=0.0412)
(Supplementary Figure 3-14).
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Figure 3-2. ATP reduction in media by L. crispatus ATCC 33820 and L. gasseri KC-1.
Bacterial eATP (µM) reduction in culture supernatant, normalized to CFU/ mL, with and
without prebiotic 0.5% (wt/vol) over 24 hours. (A) L. crispatus ATCC 33820 supplemented
with D-mannose and rate of change (µM/hr). (B) L. gasseri KC-1 supplemented with
raffinose and rate of change (ATP µM/hr). Data are displayed as mean ± SD (n=3 biological
replicates with 2 technical replicates). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, all
others are not significant.
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3.4.3 Bacteriocin production and gene regulation in the presence of ATP
Deferred growth assays and qPCR were used to determine the change in bacteriocin
production in response to ATP exposure. Several known bacteriocin producers and the
standard indicator M. luteus T-18 were used to assess bacteriocin production (Supplemental
Table 3-2). Growth into the ZOI by M. luteus T-18 when the producer was grown with ATP
was significant with Enterococcus faecalis PB4 (unpaired, two-tailed t-test, p=0.0141),
Streptococcus uberis ATCC 27958 (unpaired, two-tailed t-test, p=0.0006), Streptococcus
uberis 42 (unpaired, two-tailed t-test, p=0.0264), Streptococcus rattus BHT (unpaired, twotailed t-test, p=0.0212), Streptococcus salivarius M18 (unpaired, two-tailed t-test, p=0.0074),
and Streptococcus salivarius K12 (unpaired, two-tailed t-test, p=0.0006) (Figure 3-3).
Several bacteriocins did not inhibit M. luteus T-18 growth after 24 hours; therefore, the effect
was not observable (Streptococcus pyogenes 71-679, Streptococcus pyogenes FF22,
Streptococcus pyogenes 71-724, Streptococcus anginosus T-29, Pseudomonas aeruginosa
P1, Streptococcus zooepidermicus 4881, and Streptococcus agalactiae 74-628).
Streptococcus lactis A5 bacteriocin production was too robust, and M. luteus T-18 could not
grow, which affected the analysis. In response to ATP supplementation, bacteriocin gene
production was not significantly decreased (unpaired two-tailed t-test done with ΔΔCt
values) (Figure 3-4).
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Figure 3-3. ATP impacts bacteriocin production. Bacteriocin producers were grown with
a disk of ATP (1 µg/10 µL) after growth plates were cleaned, disks removed and used for
differed growth assays. Growth of M. luteus T-18 into ZOI after bacteriocin producer growth
quantified in ImageJ, plates pictured are representative of each bacteria. Data displayed as
growth into ZOI (%) ± SD (n=3-5) (unpaired two-tailed t-test). *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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Figure 3-4. ATP impact on bacteriocin genes in S. uberis 42 and S. uberis ATCC 27958.
Bacteriocin gene quantification with qPCR after growth with ATP (1 µg/10 µL). (A)
Streptococcus uberis 42 (B) Streptococcus uberis ATCC 27958 bacteriocin genes quantified
using qPCR. Data are displayed as Relative quantification (2 -∆∆Ct) ± SD (n=6) (unpaired twotailed t-test done with ΔΔCt values). All values are non-significant.
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3.4.4 Prebiotic and bacterial cell co-culture to examine eATP levels
Urothelial cells 5637 were cultured with bacteria and prebiotic compounds to assess the
impact of the prebiotic-probiotic combination on eATP. Supplementation of lactulose (1%)
caused significant ATP release from the urothelial cells (two-tailed t-test, p=0.0014, n=2).
There was no significant difference between the co-culture with or without lactulose
(Supplemental Figure 3-15).
D-mannose (0.5%) significantly impacted eATP uptake by L. crispatus ATCC 33820 in a coculture with E. coli IA2 and urothelial cells 5637 (Figure 3-5 and Supplemental Figure 316). D-mannose did not induce significant urothelial 5637 cell release of ATP, nor did L.
crispatus ATCC 33820 release or induce urothelial 5637 release of ATP, compared to 5637
cells alone (two-way ANOVA, n=4). There was no significant difference in eATP levels
between all treatments for the first 4 hours (Supplemental Figure 3-16). Consistently, L.
crispatus ATCC 33820 eATP levels were significantly lower than E. coli IA2 and the coculture (two-way ANOVA, p<0.0001) (Figure 3-5A). The co-culture with D-mannose eATP
level was significantly reduced compared to E. coli IA2 at 4.5, 5, and 5.5 hours (two-way
ANOVA, p<0.0001, p=0.0004, p<0.0001) (Figure 3-5A). The eATP levels in the co-culture
vs co-culture with D-mannose were significantly greater at 5 and 5.5 hours (two-way
ANOVA, p=0.0191, p=0.0101) (Figure 3-5A). L. crispatus ATCC 33820 growth was
significantly promoted in co-culture with and without D-mannose compared to alone
(unpaired, two-tailed t-test, p=0.0046, p=0.0035) (Figure 3-5B).
Raffinose (0.5%) significantly impacted eATP uptake by L. gasseri KC-1 in a co-culture
with E. coli IA2 and urothelial cells (two-way ANOVA, p<0.0001) (Figure 3-6,
Supplementary Figure 3-17). Raffinose did not induce significant urothelial 5637 cell
release of ATP nor did L. gasseri KC-1 release or induce urothelial 5637 release of ATP
compared to 5637 cells alone (two-way ANOVA, n=4). The eATP level in L. gasseri KC-1
was significantly lower than all other groups' from 2-6 hours (two-way ANOVA, p<0.0001)
(Supplemental Figure 3-17, Figure 3-6). Release of ATP by L. gasseri KC-1 was lower
compared to other treatments at all time points except 6.5 hours compared to co-culture with
raffinose (two-way ANOVA, p<0.0001) (Supplemental Figure 3-17, Figure 3-6). Coculture has significantly less eATP compared to E. coli IA2 at 5 and 6 hours (two-way
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ANOVA, p= 0.0285, p=0.0002); the two groups were otherwise comparable (Figure 3-6A).
The co-culture with raffinose had significantly reduced eATP compared to E. coli IA2 alone
at 5-6.5 hours (two-way ANOVA, p=0.0285, p=0.0048, p<0.0001, p<0.0001) (Figure 3-6A).
The eATP levels in the co-culture vs co-culture with raffinose were significantly lower at 5
hours (two-way ANOVA, p<0.0001) and significantly greater at 5.5, and 6.5 hours (two-way
ANOVA, p=0.0103, p<0.0001) (Figure 3-6A). By 4 hours of growth, L. gasseri KC-1
growth was significantly promoted in co-culture with raffinose compared to alone (two-way
ANOVA) (Figure 3-6B). Co-culture with raffinose significantly promoted growth of L.
gasseri KC-1 compared to co-culture alone at 6 hours (two-way ANOVA, p=0.0112) (Figure
3-6B). Compared to E. coli IA2 alone, E. coli IA2 growth was significantly promoted in coculture with raffinose at 5 and 6 hours (two-way ANOVA, p<0.0001, p=0.0069) and at 5
hours compared to co-culture (two-way ANOVA, p=0.0054) (Figure 3-6B). Co-culture
growth was only significantly greater than E. coli IA2 alone at 5 hours (two-way ANOVA,
p=0.0285) (Figure 3-6B).
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Figure 3-5. D-mannose increases L. crispatus ATCC 33820 eATP reduction in coculture with E. coli IA2 and urothelial cells. L. crispatus ATCC 33820 co-cultured with E.
coli IA2 and urothelial 5637 cells, with and without D-mannose; each bacterium was also
cultured alone with urothelial 5637 cells. eATP (µM) levels in minimal cell media, correlated
to a standard curve and normalized to CFU. (A) Complete screening of eATP (µM) levels in
minimal cell media correlated to the standard curve. (B) The final CFU enumeration was
taken at 5.5 hours. Data displayed as mean ± SD (two-way ANOVA with Tukey's) (n=4).
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns= not significant.
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Figure 3-6. Raffinose increases L. gasseri KC-1 eATP reduction in co-culture with E.
coli IA2 and urothelial cells. L. gasseri KC-1 was co-cultured with E. coli IA2 and
urothelial 5637 cells, with and without raffinose; each bacterium was also cultured alone with
urothelial 5637 cells. (A) eATP (µM) levels in minimal cell media, normalized to the ATP
standard curve. (B) CFU enumeration was taken every hour after the first two hours. Data
displayed as mean ± SD (two-way ANOVA with Tukey's) (n=4). *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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3.5 Discussion
This study has characterized several prebiotic candidates that promote L. crispatus ATCC
33820 and L. gasseri KC-1 growth and can impact the eATP levels produced by uroepithelial
cells and uropathogenic E. coli IA2. This dynamic relationship has previously been
undocumented and could be used to further our understanding of the management of eATP in
bladder conditions.
Lactulose and D-mannose supplementation stimulated L. crispatus ATCC 33820 growth.
Though D-mannose can enhance uropathogenic E. coli IA2 growth at higher concentrations,
it has no impact at the lower and equally effective concentration used to enhance L. crispatus
ATCC 33820 growth. Raffinose and sodium acetate supplementation enhanced L. gasseri
KC-1 and antagonized E. coli IA2.
The urogenital environment can be challenging to replicate, leading to the testing of various
media to ensure that the effect was observable with varied nutrient availability. Previous
work in our lab has identified lactulose and raffinose as potential prebiotic candidates to
address bacterial vaginosis by promoting a lactobacilli dominant vaginal microbiota 33. Dmannose has been considered for years as a potential treatment of complicated and
uncomplicated UTIs, reducing E. coli adhesion to the epithelium34,35,55. Promotion of a
lactobacilli dominated microbiota could be a novel way for D-mannose consumption to
contribute to reduced eATP in the bladder during infection. Sodium acetate consumption can
alkalinize the urine56,57, potentially leading to L. gasseri promotion, since several
lactobacilli24, including L. gasseri58, exhibit alkaline tolerance. Sodium acetate has never
been used as a prebiotic or for treatment of bladder conditions; however, it is used via
intravenous injection to alkalinize urine and serum in patients with drug intoxication 56. Oral
consumption of lactulose and D-mannose and intravenous injection of raffinose leads to
accumulation of the compounds in urine55,59–62, impacting the microbiota. Thus, these
prebiotics could help modulate the bladder environment during an infection or prevent
through the promotion of lactobacilli growth.
Reduction of eATP from the environment through uptake promotes L. crispatus ATCC
33820 and L. gasseri KC-1 growth. When cultured with ATP, both lactobacilli could
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completely reduce the eATP after 24 hours of growth and had an associated growth benefit.
There was equal ATP reduction in media by lactobacilli with prebiotic supplementation.
Similarly, prebiotic and ATP supplementation promoted the growth of lactobacilli,
suggesting that ATP could act to a certain extent like a prebiotic in nature. D-mannose
supplementation to L. crispatus ATCC 33820 resulted in a consistent rate of ATP reduction
over time. The reduction rate varied with ATP supplementation only and was significantly
lower than the D-mannose supplemented at several points despite similar cell counts.
Raffinose supplementation of L. gasseri KC-1 led to an initial increase in ATP; however, the
accelerated reduction rate accounted for this by 24 hours of growth. Raffinose
supplementation led to greater ATP reduction by L. gasseri KC-1; the rate of ATP reduction
in the first 6 hours increased with raffinose while it slowed without. In terms of clinical
relevance, when eATP levels increase in the bladder during an infection, the lactobacilli
present in the microbiota might be enhanced by the addition of a prebiotic, resulting in more
efficient pathogen clearance and decreased eATP associated symptoms. The ability of
lactobacilli to reduce higher concentrations of ATP during growth could make them
particularly suited to address bladder conditions where higher eATP plays a role in urgency
and frequency.
Bacteriocin production is a trait of many probiotic strains, improving the organism’s
competitiveness in a microbiota environment, including the urogenital tract. Utilizing known
producers, a reduction in bacteriocin effectiveness was demonstrated when an excess of ATP
was available. This phenomenon was observable in all classes of bacteriocins and suggests
that the production of these compounds could be related to ATP scavenging. Corroborating
this, pore-forming and lytic bacteriocins cause leakage of intracellular material into the
environment41, which the producing strain can then utilize for growth. Specifically,
lantibiotics have been shown to induce intracellular ATP release through bacteriocin-formed
pores into the extracellular environment 63,64. Nisin U, a lantibiotic produced by S. uberis
ATCC 27958 and S. uberis 42, had a decreased production in the deferred growth assay.
Though significant bacteriocin gene changes were not found in either strain, there was a
trend for decreased expression of nisin U and ubercin A genes in the ATP supplemented
group. Further investigation is needed to understand this interaction fully. Overall, the results
suggest that an additional role of pathogen-released ATP could be the downregulation of
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bacteriocin production by bacteria already present in the environment, allowing for easier
infection establishment. Reduction of ATP from the bladder environment by lactobacilli
could help reduce this effect.
The ability of lactobacilli to reduce eATP from an in vitro infective bladder model with
urothelial cells and an E. coli IA2 co-culture was examined. When cultured with bladder
epithelial cells, E. coli IA2 released higher ATP levels, triggering urothelial cell release of
Ca2+ through purinergic signalling39. Lactulose, D-mannose and raffinose were tested based
on their promotion of Lactobacillus growth. Lactulose proved to be less effective as it
induced high ATP release from the urothelial cells that was not seen with the other two
prebiotics. Additionally, there was no eATP reduction by L. crispatus ATCC 33820 with
lactulose compared to co-culture alone. The supernatant from cells with L. crispatus ATCC
33820 independently had significantly lower eATP levels than supernatant with E. coli IA2
and the co-culture; there was no significant release of ATP by urothelial cells or L. crispatus
ATCC 33820 when cultured together. This suggests that L. crispatus ATCC 33820 could
have a limited impact on the bladder, inducing no further eATP disruption. On the other
hand, the reduced eATP levels in co-culture suggest that L. crispatus ATCC 33820 can take
up eATP released by E. coli IA2 and any urothelial-triggered ATP release. Further research
is needed to verify this finding.
D-mannose supplementation did not stimulate L. crispatus ATCC 33820 growth but
enhanced eATP uptake in the co-culture, and raffinose similarly affected L. gasseri KC-1
eATP reduction. Growth of L. gasseri KC-1and E. coli IA2 was increased by raffinose
towards the end of the experimental time period. As with L. crispatus ATCC 33820, L.
gasseri KC-1 released ATP concentrations comparable to 5637 cells alone. An increase in
ATP was seen in the co-culture with raffinose which was also observed in the prebiotic
supplemented ATP reduction experiment; the increased ATP reduction rate accounted for
this rise within two hours. With raffinose supplementation in the co-culture, L. gasseri KC-1
reduced the E. coli IA2 eATP level entirely; the final level was comparable to L. gasseri KC1 alone. D-mannose and raffinose are promising potential prebiotics that can be used in
conjunction with L. crispatus ATCC 33820 or L. gasseri KC-1 to address and reduce eATP
from the bladder environment.
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3.5.1 Conclusion
We have demonstrated that D-mannose and raffinose have prebiotic potential; they stimulate
lactobacilli with minimal impact on uropathogenic E. coli IA2 growth and enhance eATP
reduction. The use of a urothelial cell model in this study was suitable for investigating eATP
in the bladder environment. This work implies that symptoms commonly associated with
bladder conditions such as UTI and OBA, which may be triggered by bacterial ATP, could
potentially be reduced by a prebiotic or a prebiotic-probiotic combination. Furthermore, as
the prebiotics can be found in the urine, their ingestion may enhance an individual's inherent
microbiota to help maintain a healthy state.
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3.8 Supplementary
3.8.1 Impact of Covid-19 on research
The Covid-19 pandemic had a significant impact on this research. There was limited to no
access to the research facility for five months, putting the project on hold. I had planned to
complete additional cell co-culture assays, examine Ca 2+ influx impact, repeat the ATP
reduction assay, repeat the differed growth assays with a control at pH 3.7, and compare
bacteriocin gene production is several producers. The global plastic shortage and use of
qPCR plates in covid-19 testing kits also limited my experimental options.
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3.8.2 Figures and tables
Table 3-2. Fold change in bacterial growth between control and prebiotic
supplementation
Media

TSBFree
Artificial
Urine

Artificial
Urine
VDMP

cfVDMP

cfMRS

MSM

×10
diluted
MRS
×10
diluted
MRS/LB

Prebiotic
Lactulose (1%)
Lactulose (5%)
D-mannose (1%)
D-mannose (5%)
Raffinose (5%)
Arabinogalactan (5%)
6’-O-sialyllactose (5%)
LNT (5%)
LNnT (5%)
2-O-Fucosyllactose (5%)
Lactulose (0.5%)
D-mannose (0.5%)
Raffinose (0.5%)
Lactulose (0.5%)
D-mannose (0.5%)
Raffinose (0.5%)
Lactulose (0.5%)
D-mannose (0.5%)
Raffinose (0.5%)
Lactulose (1%)
D-mannose (1%)
Raffinose (1%)
Lactulose (1%)
D-mannose (1%)
Raffinose (1%)
Lactulose (1%)
D-mannose (1%)
Raffinose (1%)
Lactulose (0.5%)
D-mannose (0.5%)
Raffinose (0.5%)
Lactulose (1%)
D-mannose (1%)
Raffinose (1%)
Acetate (3%)
Acetate (2.5%)
Acetate (1%)

L. crispatus ATCC
33820
-0.004299
-0.2547*
0.1678*
0.1899****
0.001107
0.1117
-0.08363
-0.06656
-0.03029
-0.01566
0.8358****
1.0945****
0.7616****
0.04621
0.06669
-0.04316
-0.5710****
2.0909****
-0.5217****
0.1984****
0.3103****
-0.005305
-0.01305
1.132****
0.05176
-0.8668****
-0.6812****
-0.5871****

L. gasseri KC1
-0.2993
-0.4663
0.3398*
0.7353****
-0.6575
0.009927
0.02273
-0.01402
-0.09222
-0.2226
-0.08014
-0.01723
-0.1336*
-0.04655
-0.05616
0.01325
0.05723
-0.07247
1.0382****
-0.1197**
-0.2002
0.07493**
-0.09539
-0.1734****
0.8954****
0.02204
0.08274****
0.04491**
0.7501
38.58****
4.919**
-0.02036
-0.06010*
-0.048013
-0.1510****
-0.2419****
-0.2755****
-0.3042
0.1480****
-0.2998*
0.3639****
-0.2045*
1.100****
E. coli IA2
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VDMP

Acetate (3%)
Acetate (2.5%)
Acetate (1%)

-0.5715***
-0.5721***
-0.5552***

-0.3872
-0.3075
-0.2419

*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, all others non-significant.

-0.03391****
0.2612****
1.612****
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Table 3-3. Bacteriocin producing stains, their bacteriocin(s) and bacteriocin
classification
Producer

Bacteriocin

Class

Streptococcus uberis ATCC 27958
Streptococcus pyogenes 71-679
Streptococcus lactis A5
Streptococcus pyogenes FF22
Streptococcus pyogenes 71-724
Streptococcus uberis 42

Nisin U and Ubercin A
Salivaricin A
Nisin A
Streptococcin A-FF22
Salivaricin A
Nisin U and Ubercin A

Lantibiotic and Class IIa65,66
Lantibiotic67
Lantibiotic68
Lantibiotic69
Lantibiotic70
Lantibiotic and Class IIa65,66,71

Streptococcus rattus BHT

BHT-A and BHT-B

Lantibiotic and Unknown
class II69

Enterococcus faecalis PB4

1. Bacteriocin 31
2. Enterocin 1071A
3. Enterocin Se-K4
4. Enterolysin A
5. Enterocin AS-48
6. Enterocin EJ97
7. Enterocin W alfa
8. Enterocin W beta
9. Enterocin 7B

1. Unclassified
2. Unclassified
3. Class IIa
4. Class III
5. Unclassified
6. Unclassified
7. Class IIb
8. Class IIb
9. Unclassified72

Streptococcus anginosus T-29
Stellalysin
Pseudomonas aeruginosa P1
Pyocin S1 and S2
Streptococcus zooepidermicus 4881 Zoocin A

Lytic68
S-type bacteriocins73
Bacteriocin-like peptide74

Streptococcus salivarius K12

Salivaricins A and B

Bacteriocin-like inhibitory
substance68

Streptococcus salivarius M18

Salivaricins A2, 9 and
MPS

Bacteriocin-like inhibitory
substance75

Streptococcus agalactiae 74-628

Unknown

Unknown76
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Table 3-4. qPCR primers used in this study
Target Gene

Primer Sequence 5’-3'

Accession
Number

Amplicon
size (bp)

ubaA

F: ATCGGTGGCAAAACTGTAAA
R: GCCCGTTCATGATGGAATTA

EF203953

115

ubaI

F: CTTTGCATGCTCAAGGGAAT
R: CATAGCGGATATTGGAAATCG

EF203953

216

ublA

F: GGGATAGCCTCAGGTACTGC
R: AGCTGAGGCTGAAACTGCTC

DQ650653

129

nsuA

F: TGAAGATTTTAATTTGGATCTCATCA
R: TGACAACCACAGGTTGCAGT

DQ146939

150

nsuB

F: TCCCCATATGATCTGGCAAT
R: CTGATTATCAACCCGCGAAT

DQ146939

374

gyrB

F: AATACCCATGAGGGTGGGAC
R: GCTGTCAATCCTTCACGAACA

AB238638.1

143
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Figure 3-7. L. crispatus ATCC 33820 with prebiotic supplementation in artificial urine.
24-hour growth curves of L. crispatus ATCC 33820 supplemented with 10%, 5%, 1%,
prebiotic (wt/vol) in artificial urine. Data are displayed as mean OD 600 of two biological
replicates (solid line) and non-linear fit (dashed line). K and Y-max are included to indicate
greater growth rates, bold values.
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Figure 3-8. L. crispatus ATCC 33820 and E. coli IA2 with prebiotic supplementation in
TSB-free artificial urine. 24-hour growth curves of L. crispatus ATCC 33820 and E. coli
IA2 supplemented with prebiotic in TSB-free artificial urine. Data are displayed as mean
OD600 ± SD of three-four biological replicates. Exponential growth rate constant 'K' was
compared using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 3-9. L. crispatus ATCC 33820 and E. coli IA2 with 0.5% (wt/vol) prebiotic
supplementation in artificial urine and VDMP. 24-hour growth curves of L. crispatus
ATCC 33820 and E. coli IA2 supplemented with 0.5% (wt/vol) prebiotic in VDMP and
artificial urine. Data are displayed as mean OD 600 ± SD of three biological replicates.
Exponential growth rate constant 'K' was compared using ordinary one-way ANOVA.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3-10. L. crispatus ATCC 33820 and E. coli IA2 with 1% (wt/vol) prebiotic
supplementation in VDMP, cfMRS, and MSM. 24-hour growth curves of L. crispatus
ATCC 33820 and E. coli IA2 supplemented with 1% (wt/vol) prebiotic in VDMP, cfMRS,
and MSM. Data are displayed as mean OD¬600 ± SD of three biological replicates. The
AUC was compared using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 3-11. L. gasseri KC-1 with prebiotic supplementation in VDMP, 10× diluted
MRS, and AU. 20-hour growth curves of L. gasseri KC-1 with 0.5% and 1% (wt/vol)
prebiotic in VDMP, 10× diluted MRS, and artificial urine. Data are displayed as mean
OD¬600 ± SD of three biological replicates. The AUC was compared using ordinary oneway ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3-12. E. coli IA2, L. crispatus ATCC 33820, and L. gasseri KC-1 with prebiotic
supplementation in 10× diluted LB or MRS, and VDMP. 20-hour growth curves of L.
gasseri KC-1 with 0.5% and 1% (wt/vol) prebiotic in VDMP, 10× diluted MRS, and artificial
urine. Data are displayed as mean OD¬600 ± SD of three biological replicates. The AUC was
compared using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 3-13. E. coli IA2, L. crispatus ATCC 33820, and L. gasseri KC-1 with prebiotic
supplementation in 10× diluted LB or MRS, and VDMP. 24-hour growth curves of L.
gasseri KC-1 with 0.5% and 1% (wt/vol) prebiotic in VDMP, 10× diluted MRS, and artificial
urine. Data are displayed as mean OD¬600 ± SD of three biological replicates. The AUC was
compared using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 3-14. CFU enumeration of L. crispatus ATCC 33820 and L. gasseri KC-1. Time
course CFU enumeration of (A) L. crispatus ATCC 33820 (B) L. gasseri KC-1 grown with
prebiotic 0.5% and 1µM ATP, 1µM ATP only, and media only. Data displayed as mean CFU
per ± SD (two-way ANOVA) at each time point of 3 biological replicates. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3-15. Lactulose effect on urothelial 5637 cells. L. crispatus ATCC 33820 cocultured with E. coli IA2 and urothelial 5637 cells, with and without lactulose; each bacteria
was also cultured alone with urothelial 5637 cells. Complete screening of eATP (µM) levels
in minimal cell media normalized to the ATP standard curve. Data displayed as mean ± SD
(two-way ANOVA with Tukey's) (n=2-3).
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Figure 3-16. D-mannose impact on L. crispatus ATCC 33820 reduction of eATP from
cell culture. L. crispatus ATCC 33820 co-cultured with E. coli IA2 and urothelial 5637 cells,
with and without D-mannose; each bacterium was also cultured alone with urothelial 5637
cells. Complete screening of eATP (µM) levels in minimal cell media normalized to the ATP
standard curve. Data displayed as mean ± SD (two-way ANOVA with Tukey's) (n=4).
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Figure 3-17. Raffinose increases L. gasseri KC-1 eATP reduction in co-culture with E.
coli IA2 and urothelial cells. L. gasseri KC-1 was co-cultured with E. coli IA2 and
urothelial 5637 cells, with and without raffinose; each bacterium was also cultured alone with
urothelial 5637 cells. Full screening of eATP (µM) levels in minimal cell media, normalized
to the ATP standard curve. Data displayed as mean ± SD (two-way ANOVA with Tukey's)
(n=4). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Chapter 4

4

General discussion

The work undertaken in relation to this project supports our hypothesis that lactobacilli could
be further implemented in the bladder environment to reduce extracellular adenosine
triphosphate (eATP). This is important, as high levels of eATP are thought to play a negative
role in bladder conditions, especially those involving urinary urgency and infection. By
applying specific prebiotics that have been identified in this thesis, it is feasible to promote
lactobacilli with strong ATP depleting activity and may be possible to reduce urinary
urgency.

4.1 Understanding the impact of ATP release and uptake by
bacteria
There is a known association between high urinary adenosine triphosphate (ATP)
concentrations and conditions, including; urinary tract infection (UTI), overactive bladder
(OAB), dysuria, urinary urgency incontinence (UUI) and bladder muscle contractions 1–4.
Increased urinary ATP has been used as a biomarker to diagnose UTI since at least 1971 5;
recent studies suggest that it might be used as an indicator for OAB, lower urinary
symptoms, and dysfunction1,6. Our lab has shown that uropathogenic and pathobiont bacteria
release ATP. In the bladder, this could influence smooth muscle contraction associated with
urinary contraction through purinergic signaling pathways 7. Uropathogens release ATP,
triggering purinergic host receptors to release urothelial ATP, leading to an increased ATP
concentration. Repetitive purinergic signaling contributes to the high ATP concentrations in
the bladder during these conditions. A urinary microbiome of a healthy individual may
contain ATP-reducing species that limit bacterial triggered ATP release. Further studies will
determine the extent to which reduction of bacterial ATP influences purinergic signaling in
the bladder and regulation of urgency symptoms.
It is known is that many bacteria release ATP during growth and thereby can potentially
impact purinergic signaling pathways upon the host 8–11. Although the mechanisms of ATP
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release and uptake are yet unknown, it is observable across bacteria, suggesting it may
benefit the organism. However, releasing cellular energy from bacterial cells in the form of
ATP during growth seems illogical, as we would predict a conservative approach to fuel
cellular processes. Physiologically, the release is only logical if there is a direct benefit, such
as bacterial or host communication, an energy reserve, bioenergetic molecule sharing
between microorganisms or between them and the host. The change in eATP concentrations
during growth10,12 and in response to the host8,9,13, environmental stress10,14,15, and nutrient
availability16, suggest ATP release could be a regulatable mechanism controlled by the
bacteria throughout growth. The influence on host neurotransmission and bacterial-host
communication benefits of eATP also suggest that release is purposeful and valuable 11,13.
Additionally, the bacterial ATP triggered purinergic signaling, causing host release of ATP 7
could then act as a nutritional source for the organisms. Release and uptake of ATP support
the idea that bacteria could be using the environment to store ATP for later consumption or to
share with other key symbionts.
In Chapter 2, a range of commensal and pathogenic bacteria were shown to release ATP.
During Lactobacillus crispatus ATCC 33820 and Escherichia coli IA2 growth, eATP
concentrations fluctuated, rising to peak during log-phase growth then depleting in stationary
phase. In the stationary phase, growth has ceased, but cells remain metabolically active, and
bacteria are faced with nutrient deprivation, as well as physical and chemical stresses 17. The
cells address these conditions with a reduction in size and an increase in the DNA/protein
ratio, and they adapt to survive conditions of stress and starvation 17. If ATP is available
extracellularly, this may be a means to senescence survival without active replication.
Bacteriocin production typically occurs in the late-log or stationary phase 18,19, giving the
producing strain an advantage in the competitive environment for niche and potentially
nutrients by liberating ATP from target cells. The fluctuation in eATP concentrations could
be related to the stress associated with stationary phase nutrient deprivation and competition.
Stationary phase growth is similar to the consolidation phase in Proteus mirabilis swarming;
it is a resting state during which there is an upregulation of nutrient uptake systems, central
metabolism, and respiration20. We observed a tendency to migrate towards eATP during P.
mirabilis consolidation, suggesting that the ATP may motivate directional growth through
nutrient availability, signaling, or another undiscovered method. While bacteria are growing
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and producing an abundance of ATP, the cells could release excess into the environment for
storage and reduce nutrient deprivation after exponential growth.
Following the same idea, bacteriocins contribute to the release of nutrients that can
supplement late phase survival18. It could be beneficial for bacteria to release excess nutrients
or ATP in a hostile environment if this reduces bacteriocin production. Streptococci are
prolific producers of bacteriocin21 and eATP, as we observed. Bacteriocin production
contributes to community development in streptococci through interspecies signaling,
limiting the outgrowth of a signal streptococcal strain in a co-colony22. It is possible that ATP
acts as a communication signal between species and that higher release is related to stable
colonization of several organisms. We found decreased bacteriocin production with
supplemented ATP, suggesting that ATP could limit bacteriocin production within a
microbiota. If the ATP producers are supplemented in late phase growth, the environment
might be more hospitable and able to support the survival of many species (Figure 4-1).
Bacteria could use ATP as a signaling molecule to communicate with neighbouring bacteria
and the host, influencing the environment. There are purinergic receptors found on almost all
mammalian tissues. Purinergic signals control many physiological and pathological processes
in humans, including cell proliferation, cell motility and death, development and regeneration
of body systems, neurotransmission, neuromodulation and secretion of ions or other small
molecules3,23–28. Short- and long-term trophic events can be triggered by ATP 23,28. Bacterial
ATP can influence the immune system, induce smooth muscle contractions, stimulate host
cell release of ATP, and utilize host ATP7–9,13. Purinergic receptors on the urothelium
triggered by bacterial ATP release host cellular ATP creating an ATP excess in the bladder.
Abundant urinary ATP induces Ca2+ influx triggering smooth muscle contraction and is
associated with urgency2,7,29,30. The present study showed that ATP in E. coli IA2 supernatant
could influence the directional growth of uropathogenic P. mirabilis. These results suggest
that E. coli IA2 could be influencing other pathogens, in addition to modulating the
environment7. For example, increased urinary ATP during UTI6 and OAB1 could promote P.
mirabilis growth. Taken together, these findings support the idea that bacterial ATP could
allow host and bacterial communication and influence the bladder environment.
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Generally, bacteria considered more pathogenic, or those that lead to symptomatic
presentation in the host (E. coli, Streptococcus, Gardnerella vaginalis) release higher ATP
concentrations than those considered commensal in the bladder. The most significant
producer in this study was group A Streptococcus pyogenes NGAS979, a particularly
virulent skin and mucosal infector31. Streptococci are common skin and oral cavity
colonizers and opportunistic pathogens, for which their release of ATP may be an additional
virulence factor. When ATP is applied to the epidermis, it elicits a pain response 32 which
results in inflammation23. With pain and inflammation causing agitation, an opportunistic
pathogen could become more virulent. However, this response can be reversed with a
reduction of ATP33,34. In addition, the burning associated with ATP release could lead to
disruption of the epithelial barrier allowing an infection under the skin. Significant release of
ATP by S. pyogenes NGAS979 could be contributing to virulence in one of these ways.
Further research is needed to understand why relatively large amounts of ATP are released
by this strain compared to other bacteria.
Some bacteria not considered pathogenic have been found to release more ATP than other
commensals: specifically, G. vaginalis 14018 and Limosilactobacillus vaginalis NCFB 28107
(reclassified from Lactobacillus vaginalis NCFB 2810). These are bacteria commonly found
in the reproductive and urogenital tract; G. vaginalis is associated with a disordered
microbiota and bacterial vaginosis; L. vaginalis is a commensal vaginal isolate7. Identifying
common urogenital bacteria, which could have a similar impact on the bladder to that of E.
coli IA2, supports the idea that UUI is related to bacterial ATP release and may not be easily
predictable by compositionally based 16S rRNA gene sequencing analysis. Often OAB is
defined as urgency without active infection. If the microbiota of an individual has native
species which release high ATP concentrations, this could promote pathogen growth and
cause infection. Further investigation is required into whether certain urinary microbiota
species may be a part of the disease process through this mechanism.
Ultimately the purpose behind the bacterial release of ATP is still unknown. However, this
study and others provide strong support for the idea that ATP exchange between bacteria, the
environment, and the host occurs. Bacterial-host interactions can be impacted through
purinergic signaling, with eATP acting as a neurotransmitter. Bacteria may utilize the
environment to store ATP for use in later phase growth. In addition, ATP may enable inter-
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bacterial communication and help establish colonization, promote and direct growth (Figure
4-1). With an increasing understanding of bacterial-ATP and its interaction with the host, a
more comprehensive role of eATP can be generated.
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Figure 4-1. The potential impact of ATP secretion and uptake on the bacteria, the
microbiome and the host. Excess ATP taken up by bacteria could be a source of energy in
late phase growth and a chemotaxis signaling molecule. Bacterial release of ATP could
influence bacteriocin production, intraspecies communication, and host signaling. In humans,
bacterial ATP is a neurotransmitter targeting purinergic receptors, triggering immune
differentiation, and inducing ATP release. Created using biorender.com.
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4.2 A proposed method for eATP reduction in the bladder
The stretch feeling associated with a full bladder is controlled by a system where ATP plays
a key role: as the bladder fills, urinary ATP increases and triggers Ca 2+ influx and smooth
muscle contractions29,30,35. When urgency is felt at lower bladder volumes, there are ATP
concentrations similar to those seen in a healthy full bladder2. Conversely, with a reduction
of ATP signaling there is reduced urgency36.
In Chapter 3, we examined the ability of lactobacilli to reduce ATP in vitro and the impact
prebiotics could have on this process. Both L. crispatus ATCC 33820 and Lactobacillus
gasseri KC-1 released significantly lower amounts of ATP compared to uropathogens and
were able to consume more ATP during growth than was released by any uropathogen tested.
Using media to mimic the urogenital environment, lactulose, D-mannose, raffinose, and
sodium acetate were efficacious prebiotic candidates that enhanced lactobacilli growth and
led to reduced ATP levels.
D-mannose and raffinose accumulated in the urine after administration 37–39 and had no
impact on urothelial cells in vitro. These prebiotics stimulated L. crispatus ATCC 33820 and
L. gasseri KC-1 leading to an increased ATP reduction rate. Further studies are needed to
improve this experimental model and assess whether oral or topical application of a prebiotic
can have the same effect. A prebiotic and probiotic blend could be lyophilized for
administration orally, as a vaginal suppository, cream, or gel 40. Lactulose had an adverse
urothelial cell interaction resulting in greater ATP release. However, this prebiotic could still
increase lactobacilli present in the vaginal tract41, potentially enhancing urinary tract
lactobacilli due to the interconnected microbiomes 42. Sodium acetate showed prebiotic
potential for L. gasseri KC-1 with suppression of E. coli IA2 growth. Based on another
study, this prebiotic could be used in conjunction with antibiotic erythromycin to enhance its
antibacterial effects43.
Growth of L. crispatus ATCC 33820 and L. gasseri KC-1 supplemented with ATP was
similarly enhanced as with prebiotic supplementation. However, adding a prebiotic to ATP
supplemented media had no greater impact on growth than ATP alone. In co-culture with E.
coli IA2, both L. crispatus ATCC 33820 and L. gasseri KC-1 growth was enhanced, which
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suggests the ATP release from E. coli IA2 was a stimulant. Thus, increased eATP
concentrations during infection may foster lactobacilli growth and consumption (ATP) in
individuals with abundant native lactobacilli. This interaction could contribute to UTI
resolution without antibiotic intervention, as occurs in some patients 44.
When applied to urothelial cells, lactobacilli supernatant reduced E. coli IA2 impact on Ca2+
influx and muscle contractions in vitro through purinergic receptor binding with GABA7. In
co-culture with urothelial cells and E. coli IA2, lactobacilli can reduce ATP through uptake.
Lactobacilli uptake of ATP is enhanced with prebiotic supplementation, resulting in lower
eATP concentrations than co-culture alone. Increased ATP reduction is not caused by a
greater bacterial load. In the minimal RPMI 1640 with E. coli IA2, lactobacilli might limit
eATP uptake to ensure nutrient availability in the stationary phase; the addition of a prebiotic
provides more nutrients allowing further ATP reduction. Bacteriocin production is also
related to nutrients and ATP availability. Late phase antimicrobial molecules and
bacteriocins that promote lactobacilli growth and could inhibit surrounding organisms could
be decreased in response to surplus ATP.
Secretion of ATP by L. crispatus ATCC 33820 increased up to exponential growth, while E.
coli IA2 eATP peaked before the exponential phase. This may be explained by a study that
showed that reduction in cellular respiration lowers ATP output 12. Lactobacilli glycolytic and
fermentative respiration produces less ATP, which could relate to their relatively low
secretion. During exponential growth, lactobacilli could benefit from ATP uptake, as it might
reduce the cellular respiration requirements. These are significant findings that require
further investigation to elucidate fully.
These in vitro studies appear to be a basis for ATP-related UUI regulation in a bladder by
adding lactobacilli through the application of probiotics or stimulation of indigenous strains
using prebiotics. We have demonstrated that pathogenic bacteria secrete ATP during growth,
lactobacilli can reduce ATP from culture and in vitro bladder model, and prebiotic
supplementation can enhance ATP reduction. This concept is worth pursuing clinically to
manage OAB and uncomplicated UTI. Current therapeutic options fail to address ATPrelated urgency, and this is an antibiotic-free intervention that could relieve patient symptoms
in a novel way. (Figure 4-2)
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Figure 4-2. Potential impact of lactobacilli on ATP in the bladder. (A) With a UTI, E.
coli IA2 secretes ATP, which binds to host purinergic receptors leading to calcium and ATP
influx. Increased neurotransmitters in the sub-urethral space, ATP, can stimulate the
parasympathetic pelvic nerve leading to pain and smooth muscle contractions. (B) With the
introduction of prebiotics, there might be an increase in lactobacilli and a decrease in eATP.
Thus, with the decreased ATP load, there could be reduced purinergic and parasympathetic
signaling. Additionally, lactobacilli presence reduces calcium influx through GABA
stimulation of ion channels to reduce intracellular voltage and smooth muscle contractions.
Created using biorender.com.
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4.3 Future directions
Future work should validate the findings and identify the bacterial mechanism of ATP
regulation and how it is secreted, transported across membranes, and if this is an active
process. A set of experiments with labelled ATP could be used to visualize the release,
uptake and transport through the bacterial cell45. Luciferase could be used to visualize and
track ATP movement in real-time. Plate imaging with luciferase could be used to track ATP
release or consumption by bacteriocin producers45. Imaging in conjunction with bacteriocin
detection via differed growth assay could elucidate the ATP-bacteriocin interaction. Further
studies could also interrogate how eATP operates as a signaling molecule between bacteria
and the host.
Another limitation of this study is the introduction of lactobacilli to the urinary tract. Studies
have examined probiotic and prebiotic applications to the vaginal tract 21,41,46,47, with some
positive reductions in recurrent UTI reduction and increased lactobacilli abundance.
Lactobacilli could be introduced orally, topically or with a catheter; studies on urinary
microbial abundance after introduction could be used to confirm effectivity and potential
engraftment. Application to sanitary and incontinence pads could also be examined to see if
the lactobacilli numbers increase. A synbiotic cream or gel 40 could also be assessed.
Prebiotics tested in this study are known to accumulate in the urine. Investigating an
individual’s urinary microbiota before and after consumption of the prebiotics would be
worth testing. The effect of prebiotics on eATP reduction could be tested in a human urine
model whereby urine from UTI or OAB patients and healthy controls could be supplemented
with prebiotics, then lactobacilli and eATP concentrations monitored over 24 hours.
The interaction between bacterial ATP and host purinergic signaling is being investigated
and addressed beyond the bladder. For example, Scott et al. 48 have developed a yeast-based
probiotic that responds to increased bacterial ATP in the gut by expressing purinergic
receptors to neutralize it, leading to decreased inflammation in IBD mouse models.
Understanding the dynamics between host-bacteria-ATP will lead to novel therapeutic
avenues such as those outlined in this thesis.

128

4.4 Concluding statement
This study found that a range of pathogenic and commensal bacteria release and uptake ATP
during growth. This ATP can influence the directional growth of uropathogenic P. mirabilis,
which could have implications in recurrent UTIs. In an in vitro environment, lactobacilli
were found to reduce ATP with minimal impact on urothelial cells. Thus, the addition of a
prebiotic could provide a nutrient source fostering lactobacilli growth and lead to further
reduction of ATP. During a UTI, introducing a prebiotic into a urogenital microbiota
containing lactobacilli might be sufficient to observe this effect and its benefits in an
individual suffering from UUI.
Our understanding of the role that eATP plays in bladder conditions is in its infancy. This
study has opened up new ideas aimed at improving the management of UUI in UTI and
OAB. This thesis has shown the potential for eATP reduction in the bladder by lactobacilli
when combined with prebiotic D-mannose or raffinose.
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